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ABSTRACT 
 
 
REGINA MARIE VRIKKIS. Interleukin-2 in aqueous and lipid environments: 
understanding molecular interactions that impact pharmaceutical formulation. 
(Under the direction of DR. GLORIA ELLIOTT) 
 
 
The continued development of pharmaceutical recombinant proteins as 
therapeutics necessitates a full understanding of the biomolecular interactions impacting 
structural and functional protein stability within different environments. Two such 
environments are investigated here for the therapeutic protein, interleukin-2 (IL-2). 
Aqueous surroundings are applicable in liquid formulations for storage and parenteral 
injection as well as some controlled release drug delivery strategies, while the 
pharmacokinetic targeting possibilities of a liposome nanoparticle drug delivery system 
for IL-2 dictates an understanding of molecular interactions within a lipid environment. 
Proteins often require excipients to preserve structural and functional stability in 
aqueous environments, thus we investigated a novel organic salt, choline dihydrogen 
phosphate (CDHP), which has been shown to impart increases in thermal stability of 
some model proteins. Thermal stability is of particular interest for IL-2, which 
irreversibly aggregates upon thermal denaturation. A significant increase in the thermal 
midpoint transition temperature (12.5˚C) of IL-2 was seen in the presence of high 
concentrations of CDHP (680mM). Control formulations in sodium dihydrogen 
phosphate (NaDHP), choline chloride (ChCl), and sodium chloride (NaCl) revealed that 
the DHP anion is the primary contributor towards IL-2 thermal stability. Initial 
cytotoxicity studies indicated the need for lower concentrations (<40mM), suggesting the 
need for dilution prior to in vivo administration. Bioactivity of IL-2 in the presence of 
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30mM CDHP revealed that even small amounts of CDHP can affect the bioactivity of IL-
2, demonstrating that increases in thermal stability do not necessarily lead to increases in 
bioactivity retention. 
The second aim of this work was to investigate the interaction between IL-2 and 
lipid vesicles and the clinical implications of such an interaction, including release 
kinetics and bioactivity of released protein. Liposomes are of particular interest for IL-2 
because of their potential as a lymphatic system targeting drug delivery strategy or as a 
means of decreasing the in vivo clearance rate of IL-2 in the body. Three 
phosphatidylcholine based lipids of various acyl chain lengths (DMPC, DPPC, and 
DSPC) which have a neutral charge at physiological pH and one phosphatidylglycerol 
based lipid (DSPG) which has a charge of (-1) at physiological pH were chosen for 
liposome formulations. The effect of liposome composition on IL-2 binding 
thermodynamics, IL-2 lipid saturation ratios, IL-2 release kinetics, lipid bilayer melting 
thermodynamics, and IL-2 bioactivity were studied. A positive correlation between acyl 
chain length and IL-2 binding and saturation ratios was found. Bioactivity of released IL-
2 was not significantly altered as a result of formulation into the various lipid 
compositions. Aggregation phenomena of liposomes, which were altered upon IL-2 
incorporation into each liposome formulation, impacted release kinetics. All 
phosphatidylcholine based liposome formulations disaggregated upon IL-2 addition, 
while formulations containing phosphatidylglycerol aggregated upon IL-2 incorporation. 
An IL-2 liposome interaction model is proposed to explain binding thermodynamics and 
aggregation behavior, which may facilitate the development of future IL-2 liposome 
formulations.  
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CHAPTER 1: GENERAL OVERVIEW 
 
 
1.1 Pharmaceutical Proteins and the Importance of Stability 
The advent of recombinant DNA protein technology has facilitated the development 
of protein based drugs, which now comprise a sizable portion of drugs on the market and 
under clinical development. Such drugs are advantageous in that they are very specific in 
their action. Their unique, three dimensional structural conformations allow precise 
interactions with specific biomolecules to elicit exact biochemical reactions within the 
body. However, protein based drugs are often sensitive to the thermal, chemical, and 
physical stresses that occur during production, isolation, and bioformulation (Chang & 
Yeung, 2010). Unlike small molecule based pharmaceutical formulations, proteins are 
complex, three dimensional structures that are subject to unfolding, or denaturing, upon 
exposure to stresses such as heat, pH changes, mechanical stress, and exposure to 
interfaces. The road from the initial isolation of a protein from a cell or tissue to 
application is a long one, involving exposure to many of these stresses. Understanding 
the effect of these stresses, as well as how to mitigate them, is vital to producing, 
handling, and successfully storing a structurally and functionally intact protein product. 
In order to understand the effect that certain types of stresses have on proteins, one 
must define a measure of protein stability. Protein stability is an extremely broad term, 
and can be explained in terms of structure and function, with the two concepts very 
closely related. Protein functional stability is a simple concept in that proteins have 
2 
 
specific jobs. An evaluation of the ability of a protein to carry out this task or subtasks 
can establish the functionality of the protein. The ability of a protein to function requires 
certain aspects of its primary, secondary, and tertiary (and for some proteins, quaternary) 
structure to remain intact and unmodified, and to have a certain amount of molecular 
mobility. These critical structural moieties are unique to an individual protein. Structural 
modifications as well as changes in molecular mobility that may occur during 
bioprocessing and formulation can affect the ultimate functionality of the final product. 
The effect of two bioformulation/bioprocessing conditions on the structural and 
functional stability of a pharmaceutical protein will be considered in this work: 
preparation within an aqueous formulation and integration within a nanoparticle drug 
delivery system. 
1.2 Interleukin-2 
Interleukin-2 is a therapeutic protein used to treat metastatic melanoma, the 
deadliest form of skin cancer. While the immune system naturally attempts to recognize 
and eliminate cancer cells (Burnet, 1967; Shankaran et al., 2001), some tumor cells 
continue to multiply after failing to provoke an immune response. Although localized 
tumor treatment primarily involves surgical resection, if the cancer has metastasized and 
spread to distal parts of the body, the preferred treatment options are chemotherapy or an 
immunotherapy, such as recombinant human IL-2 (rhIL-2). For simplicity, we will refer 
to clinical and laboratory grade rhIL-2 as IL-2 in this work.  
Interleukin-2 is a protein that is naturally produced by the body during an immune 
response. It is a unique cancer treatment option in that it does not interact directly with 
the tumor cells (as in chemotherapy), but combats cancer by enhancing the immune 
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system response. Upon successful binding of IL-2 with its receptor (IL2-R) on activated 
immune cells called T-helper cells, IL-2 is responsible for a signaling pathway that 
results in the activation, production, differentiation, and stimulation of relevant cancer 
fighting immune cells (Smith, 1988). IL-2 therapy has been approved by the FDA for use 
as an immunotherapeutic agent to treat metastatic renal cancer since 1992 and metastatic 
melanoma since 1998. The current approved therapeutic regimen, a systemic approach 
necessitated by the widespread distribution of cancer at these late disease stages, involves 
repeated, high dose intravenous injections of IL-2 directly into the blood stream. Such a 
dosing schedule is required to maintain an effective circulating therapeutic level because 
of the high blood clearance rate of IL-2 (Barton-Burke, 2006 ; Konrad et al., 1990; 
Rosenberg et al., 1985).  Unfortunately severe toxicity often requires cessation of 
treatment before a therapeutic benefit is attained (Rosenberg et al., 1987). 
Despite the difficulties associated with the traditional administration method, IL2 
therapy is for many patients their last hope for a cure. At these late cancer stages, 
complete remission of the cancer is an extremely unlikely scenario with most treatment 
options. Alleviation of patient pain or the extension of the patient’s life by weeks or 
months may be considered a worthy goal. The currently approved therapeutic regimen for 
IL-2 has a complete response rate of 6% and partial response rate of 10% on metastatic 
melanoma (Corporation, 2008). A complete response results in permanent cancer 
remission, while a partial response results in diminished cancer growth. This is 
comparable to other immunotherapeutic and chemotherapeutic agents such as 
Ipilimumbab (complete plus partial response rate of 10.9%  (Company, 2011; Hodi et al., 
2010)) and Decarbazine (complete plus partial response rate of 10-20%  (C. M. 
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Anderson, Buzaid, & Legha, 1995; Legha, 1989) but less than 2% complete response 
over a period of 5 years (Ahmann et al., 1989)). Because IL-2 is one of the extremely few 
metastatic melanoma treatment options that results in complete cancer remission in some 
patients, we have chosen it as the protein drug for this study. The IL-2 used clinically 
(Aldesluekin®) differs from native IL-2 in the following ways: (1) It is not glycosylated, 
(2) it has no N-terminal alanine, (3) it has serine substituted for cysteine at amino acid 
position 125, and (4) its aggregation tendencies are different. We have chosen this mutein 
for the current study. 
1.3 Degradation Pathways of IL-2 
Proteins denature via different pathways, thus it is important to be aware of what 
these typical paths are and what types of stresses may lead to this type of denaturation in 
order to formulate an appropriate strategy for dealing with them. Here we will review 
some of the most common degradation pathways of IL-2.  
Chemical degradation of IL-2 occurs via oxidation and deamidation. Oxidation 
will be addressed first. While IL-2 containes several oxidation sensitive residues 
(methionine, tryptophan, histadine, and tyrosine), it is methionine residue 104 that is most 
readily oxidized (Kunitani et al., 1986). In liquid formulations, addition of L-methionine 
can serve as a competitive antioxidant  to prevent IL-2 oxidation. Oxidation of the 
methionine residue comes into play during long term storage or in the presence of 
reducing agents such as potassium persulfate, an agent often used in making hydrogels 
(Cadee et al., 2001). Methionine oxidized IL-2 is separable by reverse phase high 
performance liquid chromatography (RP-HPLC), but it still retains full biological activity 
(M.Hora, 1990). 
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Deamidation is the deletion of an amide functional group from an organic 
compound. This results in damage to the protein side chains of amino acids asparagine 
and glutamine, with asparagine-88 being most susceptible to deamidation during long 
periods in aqueous storage. Deamidation is more likely to occur at higher temperatures, 
but does not appear to occur below 5˚C, illustrating the need for refrigeration of aqueous 
formulations of rhIL-2. The biological activity of IL-2 deamidated at asparagine-88 
retains almost the same biological activity of native IL-2  (Sasaoki, Hiroshima, 
Kusumoto, & Nishi, 1992). While biological activity of IL-2 after oxidation or 
deamidation may be retained, these forms may illicit unwanted immune responses upon 
administration due to alterations in sequence or aggregation tendencies (FDA, 2013) 
Native IL-2 has three cysteine residues at positions 58, 105, and 125, with a 
disulfide bridge forming between 58 and 105, leaving it vulnerable to mismatched 
cysteine pairing with 125. However, clinical grade IL-2 (Geigert, Solli, Woehlake, & 
Vemuri, 1993) as well as the laboratory grade IL-2 used in this study does not have a 
third cysteine residue at 125. It is replaced with a serine residue instead such that 
intramolecular disulfide scrambling is not possible. The disulfide bridge between residues 
58 and 105 is required for full biological activity of IL-2 (Geigert et al., 1993). 
Substitution or deletion of either cysteine 58 or 105, which disrupts this bridge, results in 
250 times or 8-10 times less IL-2 activity, respectively. While substitution of serine for 
cysteine at position 125 does not result in altered activity, deletion of this residue or 
residues in the vicinity of residue 125 results in a protein with negligible activity. This 
suggests that IL-2 structure around residues 58, 105 and 125 are imperative for biological 
function, with the areas around residues 58 and 125 being particularly important (Liang, 
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Thatcher, Liang, & Allet, 1986). Cleavage of this disulfide bond is promoted in the 
presence of high pH and copper ions (Geigert et al., 1993), thus pH control is extremely 
important.  
Protein aggregation can occur through several mechanisms including reversible 
self association, aggregation of chemically altered or denaturated protein, nucleation 
governed aggregation (in which the addition of native monomers to a nucleus of 
oligomers becomes thermodynamically favorable upon the attainment of a critically sized 
nucleus), and aggregation induced  by surface adsorption. Aggregation due to heat and 
shear stress results in conformationally altered protein (Philo & Arakawa, 2009). If this 
aggregation is reversible, this is not necessarily a biostability issue. For example, the 
ability of non-glycosylated IL-2, such as the laboratory grade IL-2 used in this study, to 
form heterodimers is relativity well documented, but dimerization does not appear to 
have a deleterious effect on protein functionality (Pellequer, Ollivon, & Barratt, 2004; 
Trinchieri & Clark, 1984; Welte, 1982). However, if aggregation of unfolded or partially 
unfolded protein is irreversible, protein bioactivity is permanantly lost. While many 
proteins are able to refold upon cooling after being thermally denatured, thermal 
denaturation of interleukin-2 results in irreversible aggregation of conformationally 
modified protein (K. D. Weaver et al., 2012). Thus, thermally denatured IL-2 results in 
permanent loss of biological activity.  
Excipients of IL-2 are often chosen on the basis of their ability to prevent protein 
denaturation during lyophilization due to cold stress, dehydration stress, and interfacial 
exposure. The presence of stabilizers such as amino acids, a non-ionic surfactant (Tween 
80), human serum albumin (HSA) are often included during lyophilization in order to 
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protect IL-2 from denaturation, but have a tendency to also induce aggregation and 
oxidation. Arginine and carnitine (a derivative of the amino acids lysine and methionine) 
have been included in lyophilized IL-2 formulations as amphiphilic amino acids that may 
presumably stabilize IL-2 by interacting with like regions on the similarly amphiphilic 
protein. However, such formulations are prone to aggregation upon mechanical 
perturbations after reconstitution within liquid formulations. Non-ionic surfactants 
stabilize IL-2 during lyophilization and during storage and prevent protein adsorption to 
glass and plastic surfaces by inhibiting hydrophobic interactions, but do lead to 
substantial oxidation of IL-2 (M.Hora, 1990). Human or bovine serum albumin is often 
added to IL-2 formulations in lyophilized, liquid, and liposomal formulations (P. M. 
Anderson et al., 1990; Bergers, Den Otter, Dullens, Kerkvliet, & Crommelin, 1993; 
Neville, Boni, Pflug, Popescu, & Robb, 2000) to prevent protein adsorption to glass or 
plastic surfaces (M.Hora, 1990), but may also form complexes during suboptimal storage 
conditions to affect immunogenicity of the final product (Braun & Alsenz, 1997).  
The pH at which IL-2 is most stable at varies depending on which mutein is being 
examined. In general, proteins are most stable at their isoelectric point (pI) (Mosavi & 
Peng, 2003). The particular form of IL-2 we are using in this study, des-alanyl-1, serine-
125 human interleukin-2, has a pI between 6.5 and 7.5 as determined by isoelectric  
focusing (IEF) by the manufacturer. Indeed IL-2 has been shown to be more prone to 
irreversible aggregation and protein loss at pH ≤ 6.5 (Gounili, 1999).  
Clinical grade IL-2 (Aldesleukin©) is supplied as a lyophilized cake containing 
18x106 International Units (IU) (1.1mg protein) IL-2m 50mg mannitol, 0.18mg sodium 
docedyl sulfate (SDS), 0.17mg monobasic and 0.89mg dibasic sodium phosphate. The 
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mannitol serves as a bulking agent to provide a supportive matrix for the protein during 
lyophilization. SDS serves as a solubilizing agent after reconstitution within a liquid 
formulation (Corporation, 2008; Geigert et al., 1993; T. Arakawa, 1994). Monobasic and 
dibasic sodium phosphate serves to adjust the pH of the liquid formulation upon 
reconstitution with 1.2ml water to a pH of 7.2-7.8 (Corporation, 2008; Geigert et al., 
1993).  
1.4 Project Objectives 
Given these IL-2 stability issues, innovations of therapeutic formulations that 
maintain protein functionality are clearly needed. Such formulations are not only needed 
for the storage and transport of IL-2, but also to support new directions in the 
administration of IL-2. Such a task necessitates a full understanding of the biomolecular 
interactions impacting structural and functional protein stability within different 
environments. Two such environments 
are investigated in this work: aqueous 
and lipid. Aqueous surroundings are 
applicable in liquid formulations for 
storage and parenteral injection as well 
as some controlled release drug delivery 
strategies (FIGURE 1), while the 
pharmacokinetic targeting possibilities 
of lipid based nanoparticle drug delivery system for interleukin-2 dictates an 
understanding of molecular interactions within a lipid environment. 
FIGURE 1: Exposure to aqueous environments within 
various drug storage and delivery strategies 
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1.4.1 Determination of IL-2 Stability in the Presence of a Novel Organic Excipient in an 
Aqueous Formulation 
Aqueous formulations intended for injection are traditionally preferred for protein 
pharmaceuticals due to the bioavailability concerns of other routes of administration. 
Excipients are often required in order to preserve protein structural and functional 
stability in these aqueous environments. Because maximum shelf life is traditionally 
attained by lyophilizing protein pharmaceuticals, fragile protein therapeutics are often 
stored in a freeze dried formulation. As a result, most of the literature addressing IL-2 
stability in the presence of stabilizing excipients is evaluated in the context of 
stabilization during lyophilization (M.Hora, 1990; Vemuri, 1992), which results in 
thermal, dehydration, and interfacial stresses (Carpenter, Pikal, Chang, & Randolph, 
1997; Maa & Prestrelski, 2000; W. Wang, 2000). IL-2  stability in aqueous environments 
has been evaluated in the presence of anti-oxidants (Cadee et al., 2001),  surfactants 
(Reyes et al., 2005; T. Arakawa, 1994), and as a function of external controls such as pH 
and temperature (Gounili, 1999). However, the lack of excipients for stabilization of IL-2 
within an aqueous environment provided the motivation to explore new excipients in the 
first portion of this work.  
The first aim of this work was to evaluate the impact of a novel organic salt, 
choline dihydrogen phosphate (CDHP), on IL-2 thermal and functional stability. CDHP 
has been shown to impart increases in thermal stability of some model proteins within an 
aqueous environment. Because irreversible denaturation and aggregation occurs after 
thermally induced unfolding (K. D. Weaver et al., 2012), thermal stability of IL-2 is 
extremely relevant. Furthermore, resistance to thermal stress in the presence of CDHP 
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was chosen as measure of stability because aggregation, oxidation, and deamidation 
(common degradation pathways for IL-2 (Cadee et al., 2001; Sasaoki et al., 1992; K. D. 
Weaver et al., 2012)) rates are expedited in the presence of thermal stress (Philo & 
Arakawa, 2009; Sasaoki et al., 1992), and thermal stress is a common factor in 
bioformulation and bioprocessing protocols (Gombotz & Pettit, 1995). Thermal stability 
is also often used as an indicator of shelf life (Weiss, Young, & Roberts, 2009). 
Individual ion contributions to thermal stability were probed by including control 
formulations of sodium dihydrogen phosphate (NaDHP), choline chloride (ChCl), and 
sodium chloride (NaCl) solutions. Because the biocompatibility of CDHP had not been 
established, cytotoxicity of CDHP was also evaluated. Bioactivity of IL-2 in the presence 
of CDHP was also measured by assessing the ability of IL-2 to promote survival and 
growth of an IL-2 dependent cell line. 
1.4.2 Evaluation of IL2-Lipid Molecular Interactions that Influence the Nature of IL-2 
Release Kinetics and Bioactivity, as Well as Liposome Aggregation Phenomena 
In addition to stability within an aqueous environment, the 
second aim of this study evaluated IL-2 biomolecular interactions 
within a lipid environment. Lipid environments are relevant for drug 
delivery systems such as liposomes and lipid based two phase 
emulsions (Tamilvanan & Benita, 2004) (FIGURE 2). Liposomes are 
often used as drug delivery vehicles, and the targeting ability of these 
constructs may lead to improvements in IL-2 treatment. While the 
traditional systemic administration method for IL-2 is associated with superior or 
comparable metastatic melanoma remission rates compared to other immunotherapeutic 
FIGURE 2: Lipid 
based drug delivery 
systems 
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and chemotherapeutic agents (Ahmann et al., 1989; C. M. Anderson et al., 1995; 
Company, 2011; Corporation, 2008; Hodi et al., 2010; Legha, 1989), complete and partial 
remission rates remain at 6 and 10%, respectively. Furthermore, systemic administration 
of IL-2 is associated with dose limiting toxicities that often require patients to be 
removed from treatment for management of these adverse effects. Controlled release and 
targeting delivery systems, including hydrogels (Bos et al., 2004; Cadee, de Groot, 
Jiskoot, den Otter, & Hennink, 2002), liposomes (P. M. Anderson et al., 1990; Bergers et 
al., 1993; Kanaoka et al., 2001, 2003; Kanaoka et al., 2002; Kedar, Rutkowski, Braun, 
Emanuel, & Barenholz, 1994; Neville, Boni, et al., 2000), osmotic pumps (Nishimura, 
Uchiyama, Yagi, & Hashimoto, 1986), and polymer based release systems (Hsu, Lesniak, 
Tyler, & Brem, 2005; Rhines et al., 2003), have been developed to improve upon 
traditional IL-2 therapy. Therefore, the second aim of this work sought to evaluate the 
nature of the biomolecular interactions between IL-2 and a two phase lipid-water 
liposome nanoparticle system upon formulation and release, and the subsequent effect on 
structure and function. 
IL-2 liposomes have been documented in literature (Bergers et al., 1993; Boni et 
al., 2001; Fleury, Ollivon, Dubois, Puisieux, & Barratt, 1995; Johnston, Reynolds, & 
Bystryn, 2006; Kanaoka et al., 2001, 2003; Kanaoka et al., 2002; Kedar et al., 2000; 
Kedar et al., 1994; F.J. Koppenhagen, 1997; F. J. Koppenhagen, Visser, Herron, Storm, 
& Crommelin, 1998; Kulkarni, Kasi, Tucker, & Pizzini, 1987; Neville, Boni, et al., 2000; 
Neville, Richau, et al., 2000; Pellequer et al., 2004), however there is little literature 
addressing fundamental liposomal design parameters affecting IL-2 interaction, release, 
and subsequent functionality. Because encapsulation of IL-2 within the interior of the 
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liposome requires exposing the protein to thermal and mechanical stress, we have chosen 
to adsorb the amphiphilic protein preformed liposomes (Kanaoka et al., 2001; F. J. 
Koppenhagen et al., 1998).  Because protein interaction at interfaces may result in altered 
protein structure or function, and it was the goal of this work to probe the exact nature 
and effect of such an interaction as a function of liposome composition. The effect of 
liposome composition on IL-2 binding thermodynamics, IL-2 lipid saturation ratios, IL-2 
release kinetics, lipid bilayer melting thermodynamics, and IL-2 bioactivity were 
assessed. Furthermore, because liposome vesicle size and aggregation tendencies can 
affect pharmacokinetics, the size distribution of liposomes was evaluated before and after 
IL-2 incorporation.
 
 
CHAPTER 2: GENERAL MATERIALS AND METHODOLOGIES 
 
 
2.1 Materials 
Lyophilized rhIL-2 (des-alanyl-1, serine-125 human interleukin-2) was purchased 
from GenScript USA Inc. (Piscataway, NJ). The IL-2 dependent CTLL-2 cell line was 
purchased from ATTC (Manassas, Va). RPMI 1640 culture medium and 
calcium/magnesium free phosphate buffer saline (PBS) were purchased from Mediatech 
(Manassas, VA). The IL-2 culture supplement from rat with concanavalin A (T-Stim) 
was purchased from BD Biosciences (San Jose, Ca). RPMI 1640 culture medium was 
purchased from Mediatech (Manassas, Va).  Bovine serum albumin (FBS), MEM non-
essential amino acid solution, 100mM sodium pyruvate solution, L-glutamine solution, 
HEPES, β-mercaptoethanol, penicillin, carboxy-fluorescein succinimidyl ester (CFSE), 
and streptomycin were purchased from Sigma Aldrich. Propidium iodide (PI) and trypan 
blue were purchased from Life Technologies (Rockville, MA) 
2.2 Methods 
2.2.1 IL-2 Aliquot Preparation and Storage 
Lyophilized rhIL-2 from GenScript was reconstituted in sterile conditions with 
0.1%BSA PBS at a concentration of 1mg/ml. The solution was equilibrated for 4 hours at 
4˚C, divided into 10ul aliquots, and stored at -80˚C. 
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2.2.2 Protein Concentration Determination 
2.2.2.1 Absorbance at 280nm 
Protein concentration was determined by absorbance at A280nm. A standard 
curve was prepared from freshly thawed rhIL-2 aliquots. 
2.2.2.2 Bicinchoninic Acid (BCA) Assay 
The BCA Protein Assay (Thermo Fisher Scientific Inc., Rockford, IL) was used 
according to the manufacturer's instructions to quantify protein concentration for protein 
samples that were too dilute for characterization by absorbance at 280nm. 
2.2.3 CTLL-2 Cell Culture 
CTLL-2 cells were cultured in RPMI-1640 media supplemented with 1% (v/v) 
non-essential amino acids, 2 mM L-glutamine, 1mM sodium pyruvate, 10mM HEPES, 
50μM β-mercaptoethanol, penicillin (100U/ml), and streptomycin (50μg/ml), 10% FBS. 
The supplemented media will henceforth be referred to as complete media. Growth was 
maintained at 37˚C in a 5%/95% (CO2/air) humidified chamber with the addition of 3% 
(v/v) T-stim. Cell density was maintained at 1-2 x 104 viable cells/ml and media renewed 
twice per week. 
2.2.4 In Vitro rhIl-2 Activity Assay 
The IL-2 bioactivity was determined using a cell based assay. CTLL-2 cells 
require biologically active IL-2 to survive and proliferate (Gillis & Smith, 1977), which 
can be quantified using a fluorescent cell viability marker, propidium iodide (PI), and 
proliferation marker, carboxyfluorescein succinimidyl ester (CFSE). CTLL-2 cells were 
recovered from culture suspensions, washed in RPMI-1640 culture medium (no FBS) 
twice, and re-suspended in PBS. An aliquot of 1x106 cells were stained by incubation 
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with 1μM CFSE for 8min at room temperature in a 50ml centrifuge tube covered with 
aluminum foil at room temperature.  Staining was stopped by adding an equal volume of 
FBS, and incubating in the dark for 5 minutes.  The cells were washed three times with 
complete RPMI medium. The cells were then plated at a concentration of at least 
1.25x105cells/well in a 96-well U-bottom culture plate with IL-2 under the appropriate 
experimental conditions. Control wells containing freshly prepared 0,1, and 10U IL-2 
were also prepared. After 71 hours of incubation, PI was added at a final concentration of 
0.5μg/ml, and incubation continued for another hour in the dark. At the end of 72 hours, 
the cells were recovered, washed twice, and re-suspended in PBS for flow cytometry 
analysis.
 
FIGURE 3: Assessment of IL-2 bioactivity by the ability of the protein to induce CTLL-2 cell proliferation and 
survival 
 
 
 
 
CHAPTER 3: STABILITY OF INTERLEUKIN-2 IN AN AQUEOUS 
ENVIRONMENT: EFFECT OF TRADITIONAL AND NOVEL EXCIPIENTS 
 
 
3.1 Introduction 
Understanding the biomolecular interactions of pharmaceutical proteins in 
aqueous formulations that lead to stabilizing or destabilizing effects and the therapeutic 
implications of these interactions are of paramount importance to successful formulation 
design. Bioavailability challenges dictate that protein pharmaceuticals must typically be 
administered within a liquid formulation by injection. Protein drugs are quickly 
hydrolyzed and broken down within the gastrointestinal tract, resulting in oral 
bioavailability as low as <1% (Park, Kwon, & Park, 2011). Parenteral administration 
(injection), which has 100% bioavailability, is usually the preferred method for delivering 
protein therapeutics. Liquid formulation eliminates the complexity and cost of 
lyophilization (freeze-drying) in favor of a product that is much simpler for the end user 
to employ. Liquid formulations are also more convenient at the time of administration, 
eliminating the need for a reconstitution step of a lyophilized product.  Furthermore the 
continued development of controlled release drug delivery systems requires some protein 
therapeutics to remain functional within an aqueous reservoir for an extended period prior 
to release in vivo (Fu, Klibanov, & Langer, 2000). Unfortunately, proteins in liquid 
formulation tend to degrade faster than in lyophilized formulations due to perturbations 
by surrounding water molecules. These water molecules tend to foster degradation of 
proteins by allowing more molecular flexibility and or via hydrolysis of the amino 
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linkages (Wei Wang, 1999) (Avis & Wu, 1996).  If the tendency towards protein 
degradation in liquid formulation can be diminished, prolonged storage in the aqueous 
state can be achieved and the cost of protein therapeutics can be substantially reduced. 
Since the rate and extent of chemical and physical degradation pathways are impacted by 
the solvent environment, understanding how proteins denature and how to prevent it is 
critical to maintaining a stable and functional product. 
Proteins are inherently unstable outside of their native environment; therefore 
stabilizing additives (excipients) are often added to improve shelf life. The range of 
stabilizing agents routinely employed as pharmaceutical excipients has, to date, been 
limited to a relatively small number of sugars, amino acids, polymers, salts, and 
detergents (Maclean, Qian, & Middaugh, 2002). Recently, various low melting point 
organic salts have been reported to stabilize proteins and DNA, decrease protein 
aggregation, and protect against thermal denaturation, raising the possibility of their use 
as additional excipients in pharmaceutical protein formulations (Byrne, Wang, Belieres, 
& Angell, 2007; K. Fujita, M. Forsyth, D. R. MacFarlane, R. W. Reid, & G. D. Elliott, 
2006; Vijayaraghavan, Izgorodin, Ganesh, Surianarayanan, & MacFarlane; R. M. 
Vrikkis, Fraser, Fujita, Macfarlane, & Elliott, 2009). It has been reported that a 
combination of kosmotropic (water structure-making) anions and chaotropic (water 
structure-breaking) cations can stabilize proteins in aqueous solution, and this criteria can 
be employed to design organic salts that stabilize therapeutic proteins in liquid 
formulation (Constatinescu, Herrmann, & Weingartner; K. Fujita et al., 2007; Ru, 
Dordick, Reimer, & Clark, 1999). One such organic salt, choline dihydrogen phosphate 
(CDHP), has been reported to extend the shelf life of several model proteins (including 
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cytochrome C, lysozyme, and ribonuclease A) when formulated with 20% (v/w) water, 
supporting the retention of structure and activity of these proteins (K. Fujita et al., 2006; 
K. Fujita et al., 2007; R. M. Vrikkis et al., 2009). Stabilization effects have also been 
observed in model proteins when using lower concentrations (<40 wt %) of this salt 
(Constatinescu et al.; K. D. Weaver et al., 2011). A 3 year shelf life of cytochrome c at 
room temperature has been seen by Fujita et al in 80% w/w CDHP (Kyoko Fujita et al., 
2007). Full functional activity of lysozyme has been maintained after room temperature 
storage of lysozyme in 80% w/w CDHP (R. Vrikkis, MacFarlane, & Elliott, 2009). A 
20˚C increase in the thermal transition temperature of ribonuclease A in the presence of 
4M CDHP (pH 7.0) has been reported, as well as an increase the reversibility of the 
reversibility of protein thermal denaturation from 5 to 80% in 0.1M CDHP 
(Constantinescu, Herrmann, & Weingärtner, 2010). 
Protein structure is sensitive to many external, environmental conditions including 
temperature, pH, and concentration of denaturing or stabilizing solvents. Interleukin-2 is 
prone to several denaturation pathways including chemical, physical/mechanical, and 
thermal denaturation. Chemical denaturation pathways relevant for IL-2 include 
oxidation and deamidation. However, these pathways can be prevented with the use of 
antioxidants and organic solvents, respectively. Furthermore, the oxidized and 
deamidated forms of IL-2 have been shown to retain similar bioactivity and functionality 
as their native forms (Cadee et al., 2001; K. Sasaoki, 1989; Sasaoki et al., 1992; 
Wakankar & Borchardt, 2006). Physical denaturation pathways due to mechanical 
stresses such as agitation or exposure to an interface can occur via aggregation. If 
aggregation is reversible, and the protein refolds back into its native conformation, this is 
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not a stability issue. Aggregation of native IL-2, for example, can be prevented in the 
presence of sodium dodecyl sulfate (Arakawa, Philo, & Kenney, 1994). However, 
irreversible aggregation leads to irreversible losses in bioactivity. Thermal denaturation 
of many proteins is reversible upon cooling. However, IL-2 undergoes irreversible 
thermal denaturation and aggregation (Advant, Braswell, Kumar, & Kalonia, 1995; K. D. 
Weaver et al., 2012).  
Therefore, thermal stability is an important parameter to consider for biologically 
active therapeutic IL-2 formulation, and is relevant for bio-preservation, protein storage, 
and bioformulation into some drug delivery systems (Maa & Prestrelski, 2000; Pellequer 
et al., 2004). Understanding this denaturation pathway and protective measures to prevent 
thermal denaturation may aid in a more rational process and formulation design. 
Furthermore, because certain degradation pathways (oxidation, deamidation, aggregation) 
may occur more quickly at higher temperatures (Cadee et al., 2001; Sasaoki et al., 1992; 
K. D. Weaver et al., 2012), exposure to thermal stress allows one to study protein 
resistance to such pathways in an accelerated manner. 
Protein structure is stable up to a temperature termed the onset temperature 
(Tonset) at which the first protein unfolding event is detectable. The temperature at which 
native and unfolded protein populations exist at a 1:1 ratio occurs at a critical temperature 
designated as the thermal midpoint transition temperature (Tm). The Tm for a given 
protein can depend on environmental conditions (pH, ionic strength, concentration of 
denaturants/stabilizers). As thermal energy continues to be added to the system such that 
the activation energy required for denaturation is transferred to the protein and the system 
temperature exceeds past the Tm, it becomes thermodynamically favorable for the protein 
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to unfold or denature. The disruption of native protein structure(s) is accompanied by 
heat absorption, measurable calorimetrically as an enthalpy heat change (ΔH). It may or 
may not be reversible (or partially so), with aggregation of denatured protein typically 
accompanying irreversible unfolding.  Thermal denaturation can be monitored by 
calorimetry, circular dichroism (CD), nuclear magnetic resonance (NMR), X-ray 
crystallography, and Fourier transform infrared spectroscopy (FTIR). 
CDHP has been shown to extend the shelf life of model proteins when used at 
high concentrations as a solvent, and increase thermal stability of model proteins when 
used at lower concentrations. Further studies are needed to understand the mechanism of 
stabilization in different concentration ranges, to identify possible differences between 
the use of CDHP with relatively stable model proteins and less robust therapeutic 
proteins such as IL-2, and to extend biocompatibility studies to better anticipate possible 
complications of in vivo injection. The aim of the current study was to investigate 
effectiveness of CDHP as an excipient for use in IL-2 aqueous formulation. This is the 
first time a therapeutic protein such as IL-2 has been formulated with this novel solvent. 
We also determined the maximum concentrations that elicit no adverse cytotoxic effects 
in vitro following chronic exposure. In doing so we sought to define the effect of low 
concentrations of CDHP on IL-2 structure and function, as well as the biological activity 
of CDHP, using complementary in vitro models of splenocyte and melanoma cell 
cultures. Furthermore, we attempted to elucidate possible molecular interaction 
mechanisms responsible for any stabilizing or destabilizing effects on IL-2 thermal 
stability and bioactivity. 
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3.2 Materials and Methods 
3.2.1 Materials 
Lyophilized rhIL-2 was obtained, prepared, and stored as previously described in 
Chapter 2. CDHP was prepared in the MacFarlane laboratory, as previously reported 
(Fujita, MacFarlane, & Forsyth, 2005; Kyoko Fujita, Maria Forsyth, Douglas R. 
MacFarlane, Robert W. Reid, & Gloria D. Elliott, 2006; Kyoko Fujita et al., 2007). The 
B16-F10 mouse melanoma cell line was purchased from the National Cancer Institute 
Tumor Repository (Frederick, MD). Dulbecco’s modified Eagle medium mixture F12 
(DMEM), resazurin, sodium bicarbonate (NaHCO3), choline chloride, and red blood cell 
lysis buffer were purchased from Sigma-Aldrich (St. Louis, MO). Sodium dihydrogen 
phosphate and sodium chloride were purchased from VWR International. 0.25% 
trypsin/EDTA was purchased from Life Technologies (Rockville, MA). A bicinchoninic 
acid (BCA) protein assay kit was purchased from Thermo-Fisher Scientific 
(Waltham,MA). 
3.2.2 Solution properties 
Solution osmolarities were measured using a vapor pressure osmometer (Wescor 
Vapro 5520, Logan, UT, USA).  
3.2.3 IL-2 Resistance to Thermal Denaturation in 0-680mM CDHP 
Resistance to thermal denaturation of IL-2 in aqueous solution was evaluated by 
heating IL-2 from a control temperature of 4˚C to a temperature between 45˚C-85˚. 
Samples were then cooled back to 4˚C to evaluate irreversible thermal denaturation. 
Aliquots of IL-2 (125 pg/mL) were diluted in PBS containing 0.1% (w/v) BSA and 
supplemented with CDHP pH 7.4 (0–680 mM). Control solutions of IL-2 in 680mM 
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NaH2PO4 (NaDHP), 680mM ChCl, and 680mM NaCl were prepared in a similar 
manner. All samples were heated to 45–85˚C in a dry bath incubator (Thermo Fisher 
Scientific). The temperature was monitored using a K-type thermocouple with a HH314A 
humidity temperature meter (Omega, Stamford, CT). Once the samples reached the 
prescribed temperature, they were immediately cooled to 4˚C prior to analysis by a 
sandwich ELISA. 
3.2.4 Effect of Prolonged Exposure of CDHP to IL-2 
To examine the effect of prolonged exposure to CDHP on IL-2, 125 pg/mL IL-2 
in 0.1%(v/v) BSA PBS was supplemented with 0–60 mM CDHP with and without an 
appropriate amount of NaHCO3 to maintain the pH 7.2. Samples were incubated in a 
water bath (IsoTemp 210, ThermoFisher Scientific) at 37˚C, removed at 24 or 48 hours, 
and stored at 4˚C prior to analysis by a sandwich ELISA. 
3.2.5 rhIL-2 Binding Ability Retention by Sandwich ELISA 
Structural integrity of IL-2 was inferred by evaluating its binding ability using a 
luminescent sandwich rhIL-2 enzyme-linked immunosorbent assay (ELISA) (Thermo-
Fisher Scientific, Waltham, MA). This 
assay requires two structurally relevant 
conformational epitopes to remain intact in 
order for binding to occur (Byrne et al., 
2007), as shown in FIGURE 4. While an 
ability of IL-2 to bind and lead to a 
luminescence signal does not necessarily 
indicate structural and functional integrity, 
FIGURE 4: A sandwich ELISA requires the presence of 
two structurally intact binding sites on IL-2. 
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an inability to bind does indicate structural alteration to the protein. This method is a 
quick, efficient method to screen excipients.  All samples were assayed in triplicate for 
each temperature point.  
3.2.6 Cytotoxicity Assays 
3.2.6.1 Rezasurin Reduction Assay 
Cytotoxicity of CDHP was investigated as described in (O'Brien, Wilson, Orton, 
& Pognan, 2000) using a cell line (B16-F10 melanoma cells) and primary cells 
(splenocytes). Cells were plated (1 x 105 cells/well for splenocytes, 1 x 104 cells/well for 
B16-F10 cells) and cultured in 96-well plates in complete culture medium in the presence 
of 0-80mM CDHP. Because of the ability of CDHP to lower the pH of the media, the 
effect of buffering to pH≥7.2 with 0.15-0.33% (w/v) NaHCO3 was also investigated. To 
maintain splenocyte growth, cultures were further supplemented with 500U/ml IL-2. 
After a prescribed length of time (4 hours for splenocytes, 18 hours for B16-F10 cells), 
rezasurin was added to a final concentration of 43.7μM. At 24 hours rezasurin reduction 
was measured colorimetrically (530/590 nm) (FIGURE 5). 
3.2.6.2 Trypan Blue Exclusion Assay 
A trypan blue exclusion assay was used to assess cytotoxicity effects CDHP. 
Cells were plated (5 x 105 cells/well for splenocytes, 2 x 105 cells/well for B16-F10 cells) 
and cultured as described in the resazurin reduction assay. At 24 hours cells were 
removed from the wells, stained with 0.04% (w/v) trypan blue, and total cell counts and 
viability were assessed using a Countess® automatic cell counter (Life Technologies, 
Rockville, MA) (FIGURE 5). 
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FIGURE 5: Cytotoxicity assays. Top: Rezasurin reduction assay. Bottom: Trypan blue assay. 
 
 
 
3.2.7 CTLL-2 Activity Assay 
IL-2 biological activity was measured by flow cytometry using a CTLL-2 reporter 
cell line. CTLL-2 cells were plated and cultured as previously described in the presence 
of 0,1, or 10 international units (IU) IL-2 with 0, 30, or 60mM CDHP buffered in 
NaHCO3 (pH≥7.2). Cell viability and proliferation was quantified as defined in the 
previous chapter. 
3.2.8 Statistical Analysis 
All results are expressed as the means ± standard error of the mean (SEM) unless 
otherwise indicated. A one or two way ANOVA was used when appropriate to compare 
results from samples ±CDHP. Prism 5 software (Graphpad Software Inc., La Jolla, Ca.) 
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was used to perform statistical analysis. A p<0.05 was considered to be statistically 
significant. 
3.3 Results 
3.3.1 Effect of Aqueous Formulation Composition During Heating on Binding Ability 
Retention 
Previous work in our lab evaluated the effect of CDHP on protein structure and 
thermal stability. The far-UV spectropolarimetry at 222nm was measured as IL-2 was 
thermally denatured and the unfolding temperature (Tm) was assessed, and it was found 
that the presence of CDHP increased the Tm of IL-2 (K. D. Weaver et al., 2012). This 
observation established a temperature range and CDHP concentration range to enable 
further investigation of IL-2 stability in clinically relevant formulations. The Tm values of 
IL-2 with and without CDHP present in solution are reported again here: (1) 30mM 
CDHP pH 7.4: Tm=60.2°C, (2) 185mM CDHP pH 7.4: Tm=63.0°C, (3) 680mM CDHP 
pH 7.4: Tm = 74.2°C, and (4) 30mM sodium dihydrogen phosphate (NaDHP): Tm 
=61.7°C pH 7.4. The experimental error in determining the Tm was 1˚C, so there was no 
statistical difference found between the Tm of IL-2 prepared in the control, 30mM 
NaDHP, and 30 or 185mM CDHP. However a significant increase in Tm was found when 
IL-2 was formulated in a 680mM CDHP solution. Interestingly, a comparison of IL-2 
secondary structure in 30mM NaDHP and 30mM CDHP revealed an increase in ordered 
secondary structure content (α-helix and β-sheet content), suggesting an overall 
tightening of tertiary structure in the presence of CDHP as opposed to NaDHP which 
became more exaggerated at higher (up to 680mM) concentrations of CDHP (K. D. 
Weaver et al., 2012).  
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In the current work, the structure and function following heating IL-2 to 
temperatures below and above the Tm was evaluated in the presence of CDHP. A 
sandwich ELISA assay measures the ability of the protein to bind at two structurally 
relevant epitopes, providing an insight into conformational changes that may impact 
binding ability retention. It is important to note that the ELISA method does not provide a 
complete profile of structural integrity, and an ability to bind at these two epitopes does 
not necessarily indicate complete structural integrity. However an inability to bind does 
indicate significant structural alteration to the protein. Protein samples were heated from 
45˚C to 85˚C, cooled immediately upon reaching the desired temperature, and evaluated 
using an ELISA. Several formulations were tested. We previously established 680mM as 
an appropriate CDHP concentration to impart a significant increase in the thermal 
stability of IL-2. In order to probe individual ion (choline and dihydrogen phosphate ions, 
specifically) contributions to protein thermal stability, a 680mM NaDHP and 680mM 
choline chloride formulation were also investigated as salt based excipients. Sodium 
chloride (NaCl), was included to enable comparison to a common inorganic salt. Each 
formulation was buffered to a pH of 7.4, and osmolality was also assessed. Solution 
osmolality measurements did not differ by more than 5% (CDHP = 1520 
mmol/kg,NaDHP = 1530 mmol/kg,ChCl = 1501 mmol/kg, and NaCl = 1520 mol/kg). 
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Using the ELISA method, IL-2 binding ability retention was not significantly 
impacted below the Tm (45˚C-60˚C) in any formulation (FIGURE 6a-d). Similar results 
were seen for IL-2 formulated in a control formulation of 0.1%BSA. At temperatures 
exceeding 60˚C, a significant decrease in structurally intact IL-2 concentration was seen 
in the 680mM ChCl, 680mM NaCl, and control formulations (FIGURE 6a-b), with only 
72 ± 5.6, 62.5 ± 3.6%, 66 ± 4.7% structurally intact protein left at 65˚C, respectively. 
This effect was further exaggerated at increasing temperatures where nearly 20% further 
loss was seen with every 5˚C increment. Significant decrease in binding ability retention 
occurred at 65˚C in control IL-2 solutions formulated in 0.1% BSA PBS (66±4.7%). 
FIGURE 6: rhIL-2 formulated in 680mM pH7.4 CDHP and 680mM NaDHP remains structurally intact when heated. 
Sandwich ELISA measurements of rhIL-2 concentrations formulated in (a) 680mM ChCl pH7.4, (b) 680mM NaCl 
pH7.4, (c) 680mM NaDHP pH7.4, and (d) 680mM CDHP pH 7.4 versus no CDHP control (white bars), and heated at 
temperatures ranging from 45°C to 85°C. Data are expressed as mean relative rhIL-2 concentrations ±SEM, normalized 
to the initial amount (T0) of protein. n=9; *: p<0.05; **: p<0.01. Comparisons are made to the control formulation at 
each given temperature. 
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At temperatures ≥65˚C, IL-2 formulated with 680mM NaDHP and 680mM 
CDHP retained a significantly larger portion of intact protein as compared to the control 
solutions (83.6±1.3% and 89.1±2.1%), losing only approximately 10% with every 5˚C 
increment (FIGURE 6c-d). Overall, IL-2 formulated in 680mM NaDHP and CDHP 
retained a larger amount of intact protein up to 23.3˚C above the Tm as compared to the 
control (19.7 ± 2.8% IL-2 incubated alone vs. 45.7 ± 3.9% in NaDHP and 46.8 ± 1.6% in 
CDHP formulation at 85˚C). 
3.3.2 Effect of Aqueous Formulation 
Composition During Prolonged Exposure to 
CDHP on Binding Ability Retention 
To determine the effect of 
prolonged exposure of CDHP on IL-2 
structural integrity, IL-2 was incubated with 
0, 30, and 60mM CDHP (± NaHCO3 to 
buffer to pH≥7.2) at 37˚C in sterile 
conditions for 24 and 48 hours. A 
significant decrease in binding ability after 
24 hours was seen in samples incubated 
with CDHP, with no further decrease seen 
when incubation length was extended to 
48hours (FIGURE 7a). This effect was 
FIGURE 7: rhIL-2 remains structurally intact after a lasting 
exposure to near-isosmotic buffered CDHP. Sandwich 
ELISA measurements of rhIL-2 concentrations incubated 
24 h (white bars) and 48 h (black bars) in 30–60 mM 
CDHP (upper panel), or CDHP in NaHCO3 (pH ≥ 7.2) 
(lower panel). Data are expressed as mean relative rhIL-2 
concentrations ± SEM, normalized to the initial amount 
(T0) of protein. n = 6; *: p<0.05. 
29 
 
nullified when pH was maintained ≥7.2, with a slight decrease in intact protein occurring 
between 24 and 48 hours incubation in the presence of buffered 60mM CDHP (FIGURE 
7b). 
3.3.3 Cytotoxicity of CDHP Formulations 
Depending on the site and mode of in vivo delivery of a CDHP containing 
formulation, chronic cellular exposure levels to CDHP could vary considerably. While it 
was not the goal of this work to evaluate the biocompatibility of CDHP it is of interest to 
FIGURE 8: Near-isosmotic CDHP is not cytotoxic when buffered in vitro. Primary splenocyte culture (a) and B16F10 
cell line (b) viability, after 24 hours of chronic exposure to 0-80mM CDHP (left panel), or CDHP in NaHCO3 
(pH≥7.2) (right panel), as measured by trypan blue exclusion (circle) and resazurin reduction (square) assays. The 
white bars indicate splenocyte viability culture in IL-2-free media containing 80mM CDHP. Data are expressed as 
mean relative cell viability, normalized to no CDHP control samples ±SEM, and compared to culture media pH 
(dashed line). n=6 for splenocytes and n=9 for B16F10 cells. 
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determine whether or not CDHP must be eliminated as a possible pharmaceutical 
excipient on the basis of cytotoxicity. Such a biocompatibility issue is extremely relevant 
to the development of a therapeutic IL-2 formulation. Here we investigated the effect of 
CDHP on primary splenocyte cultures exposed to 0–80mM CDHP concentrations in 
complete RPMI culture medium. 
At fairly dilute concentrations of CDHP (10mM), complete RPMI culture media 
pH decreased from 7.3 to 7.0, ultimately decreasing to pH 6.7 above 30mM CDHP. 
These conditions were found to be cytotoxic to splenocytes according to the trypan blue 
assay (FIGURE 8). Splenocyte culture viability decreased significantly at 40mM CDHP 
(88±7.8%, p<0.05). At 80mM CDHP, viability decreased further to 37.7±8.2. Because 
splenocyte viability decreased to 50% after 24 hours of incubation in the absence of a 
100IU IL-2/well supplement (data not shown), IL-2 was present in all culture wells. To 
determine if the ultimate cytotoxic effects seen by unbuffered CDHP was primarily due 
to deleterious effects on IL-2 or on the splenocytes themselves, a control well was added 
containing 80mM CDHP (no NaHCO3) and no IL-2. This lead to no statistical difference 
in cell viability (37.7±8.2% with IL-2 versus 23.4±5.9%) suggesting cytotoxic effects 
seen were not primarily due to denaturation of IL-2. 
To discern whether cytotoxicity was due to pH changes or to the CDHP 
concentration itself, the solution was buffered to pH ≥7.2 by adding an appropriate 
amount of NaHCO3 to 0-80mM CDHP solutions. This lead to approximately 100% 
viability of splenocytes retained upon incubation with buffered 80mM CDHP for 24 
hours. From this data, we can conclude that any cytotoxic effects induced by CDHP on 
splenocytes can be negated by buffering to pH ≥7.2. 
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Interestingly the rezasurin reduction assay did not mirror the results obtained by 
the trypan blue exclusion assay. Viability appears to increase upon the addition of CDHP 
(no NaHCO3). However, this apparent viability increase can actually be interpreted in 
terms of an increase in metabolic cell stress, because the resazurin reduction assay is a 
cell metabolism based assay (Rampersad, 2012). At concentrations 10-40mM CDHP, 
there was an apparent hormetic effect in which an increase in relative resazurin reduction 
was observed before a return to baseline rezasurin reduction was observed at 
concentrations of 50-80mM CDHP. Such an effect was negated when samples were 
buffered with NaHCO3 (FIGURE 8). 
3.3.4 Effect of Formulation Composition During Heating on Ability to Support IL-2 
Dependent Cell Line 
Structural integrity is often a prerequisite for IL-2 biological activity (Shu-Mei 
Liang, 1986), but is not the only requirement. Biological activity of IL-2 was assessed 
using the CTLL-2 cell line, a murine cytotoxic T cell line that requires IL-2 to survive 
and proliferate (Gillis & Smith, 1977). A CDHP concentration of 30mM was chosen 
based on the result of the initial cytotoxicity studies that indicated a cytotoxic effect 
>30mM CDHP (FIGURE 8a). This concentration also avoided any osmotic stress effects 
upon CTLL-2 cells, which could obscure data representing interaction site between IL-2 
and IL-2R displaying CTLL-2 cells. Furthermore, dilution in vivo upon administration 
will likely result in a lower CDHP concentration present at the interaction of IL-2 and IL-
2R positive cells.  In the absence of IL-2, there were no significant differences in cell 
death between control samples (no CDHP) or samples incubated in 30 mM CDHP with 
NaHCO3 (pH ≥ 7.2) (FIGURE 9a, 18.4 ± 2.5 and 15.5 ± 1.5% cell death, respectively). 
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Furthermore, in samples formulated in the absence of IL-2, no significant differences 
were observed in cell proliferation between samples incubated with and without CDHP 
(FIGURE 9b). 
As expected, increasing the amount of rhIL-2 in cell culture medium significantly 
reduced CTLL-2 cell death while increasing the proportion of cells undergoing 
proliferation in a dose dependent manner FIGURE 9a-b. Cell viability was not 
significantly decreased in samples containing 1 and 10IU IL-2 in the presence of 30mM 
CDHP (FIGURE 9a). However, in samples containing 1 and 10IU IL-2 and 30mM 
CDHP, the percentage of proliferating cells was diminished (from 43±5.7% to 28±5.1% 
in samples containing 10IU IL2, p<0.01). Collectively these results suggest that even at 
concentrations as low as 30mM, CDHP does have an adverse effect on IL-2 bioactivity as 
evidenced by a reduction in the ability of CTLL-2 cells to proliferate.  
 
 
 
FIGURE 9: rhIL-2 activity decreases when formulated in buffered 30mM CDHP. Flow cytometry analysis of CTLL-2 
cell viability (a) and proliferation (b), respectively measured by propidium iodide and carboxyfluorescein succinimidyl 
ester stainings, after 24 hours stimulation with 1-10IU rhIL-2 in presence (black bars) or absence (white bars) of 
30mM CDHP in NaHCO3 (pH≥7.2). Data are expressed as mean percentile of dead or proliferating cells ±SEM, among 
total cells in each sample. n=9 for both assays. 
 
 
33 
 
 
3.4 Discussion 
In this work, the stability of IL-2 in an aqueous environment in the presence of a 
novel excipient, CDHP, was investigated. Resistance to thermal stress was chosen to 
measure the stabilizing/destabilizing effects upon IL-2. CDHP was chosen for study as a 
possible excipient for IL-2 based upon its ability to increase the Tm of model proteins 
such as lysozyme and cytochrome c in previous work (Kyoko Fujita et al., 2006; Kyoko 
Fujita et al., 2007; R. Vrikkis et al., 2009). The Tm, which is the temperature at which the 
folded and unfolded proteins exist in a 1:1 ratio, is often used as a measure of thermal 
stability. A higher Tm indicates a more thermally stable protein (Cooper, Johnson, Lakey, 
& Nollmann, 2001). However the concentrations studied in these investigations were 
extremely high (≥80% w/w). While this range may be appropriate for storage 
applications, such a high concentration is not easily injectable into the body without 
dilution. Therefore we chose to investigate the use of CDHP to thermally stabilize IL-2 at 
concentrations which might be appropriate for injection or continuous release devices. 
We have previously published evidence that the presence of 680mM CDHP (pH 
7.4) resulted in an increase in the Tm of IL-2 by 12.5˚C (K. D. Weaver et al., 2012). 
While an increase in thermal stability was seen, the thermal denaturation pathway for IL-
2 remained irreversible in both 185 and 680mM CDHP formulations as evidenced by 
precipitation of aggregated protein upon cooling. Irreversible aggregation upon IL-2 
unfolding has been observed elsewhere in the presence of 5% w/v glucose and 10mM 
sodium acetate, pH 4.0 (Arakawa, Philo, & Kita, 2001). Because IL-2, unlike lysozyme 
and cytochrome c (K. D. Weaver et al., 2012), does not refold upon cooling, an increase 
in the Tm is extremely relevant. 
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It is known that protein stability is greatly influenced not only by its interaction 
with water, but by how any other co-solvent molecules present interact with the water 
molecules around the protein (Zhao et al., 2006). Salts containing a mixture of chaotropic 
cations (ions that preferentially interact with the protein itself) and kosmotropic anions 
(ions which preferentially interact with surrounding water molecules) have been shown to 
optimally stabilize proteins (Kyoko Fujita et al., 2007; Zhao et al., 2006).  In this work, a 
similar increase in thermal stability was seen for IL-2 in both 680mM CDHP and 680 
NaDHP formulations (pH ≥7.2), indicating that the kosmotropic anion, dihydrogen 
phosphate, is the primary contributor to thermal stability. Protection against protein 
thermal denaturation in the presence high concentrations of kosmotropic anion containing 
salts via non-specific interactions has been observed elsewhere in literature (Komsa-
Penkova, Koynova, Kostov, & Tenchov, 1996; Tadeo, Pons, & Millet, 2007; Vonhippel 
& Wong, 1964; Yamasaki, Yano, & Aoki, 1991). Because kosmotropic anions 
preferentially interact with water molecules surrounding the protein, they are able to 
stabilize proteins via a salting-out effect (Arakawa, Bhat, & Timasheff, 1990; Zhao et al., 
2006) essentially shielding the protein from potential denaturing interactions with the 
surrounding water molecules. 
The stabilizing ability of specific ions has been ranked on the well-known 
Hoffmeister series. While dihydrogen phosphate ranks as a stabilizing kosmotropic ion, 
the chloride ion is ranked nearly in the middle. This suggests that chloride has a relatively 
impartial role in protein stability and solubility (Zhang & Cremer, 2006), hence the salts 
containing the strongly kosmotropic dihydrogen phosphate anion are more likely to 
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prevent thermal denaturation than those containing a neutrally poised anion, such as 
sodium or choline (Zhang & Cremer, 2006). 
Surface tension effects may also play a role in the observed increase in thermal 
stability of IL-2 by CDHP. Organic salts have been observed to increase the surface 
tension of solvents in direct proportion to their concentration in solution. Thermal 
stability, as measured by an increase in Tm, has been shown to directly correlate with the 
surface tension of organic salt solutions for a range of proteins, with variations between 
proteins attributed to  differences in their physico-chemical properties (Kaushik & Bhat, 
1999). The increased solvent surface tension preferentially stabilizes the folded protein 
conformation over the denatured one, which has a much higher surface area than the 
folded state (Tadeo, Lopez-Mendez, Castano, Trigueros, & Millet, 2009). We have 
observed a concentration dependent effect on IL-2 thermal stability (K. D. Weaver et al., 
2012), suggesting that the increased surface tension as CDHP concentration increases 
may also be playing a role in the stabilizing effect of CDHP on IL-2. 
It should be noted that because the phosphate containing salts require the addition 
of some sodium hydroxide to increase the pH, the ionic strength of these solutions are 
likely  marginally higher than the chloride containing solutions, but the similarity in the 
osmolality of these solutions would suggest that this difference would be modest. Ionic 
strength can certainly play a part in protein stability (Yamasaki et al., 1991), but in the 
absence of detailed studies on the speciation of ions in solution it is difficult to uncouple 
ionic strength as a stabilization effect in the current study. It is likely that the charge-
shielding effects of high ionic strength formulations (Miki, Kakuyama, & Soda, 1997), 
together with stabilizing increases in surface tension are both contributing to some degree 
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to increases in thermal stability. However, the dramatic difference in the thermal stability 
observed between solutions containing different anions would suggest that the anion 
kosmotropicity is the dominant stabilizing effect. 
Unlike previous studies using model proteins (Kyoko Fujita et al., 2007; R. 
Vrikkis et al., 2009), data from these studies provide evidence of protein activity changes 
at CDHP concentrations as low as 30mM, which led to decreased IL-2-induced CTLL-2 
cell proliferation in vitro. As opposed to lysozyme, IL-2 does not exert its biological 
activity by catalyzing enzymatic reactions. Instead IL-2 binds to a high-affinity receptor 
consisting of three subunits: IL-2Rα (p55), IL-2Rβ (p75) and γc(p64). These receptors 
are expressed by specific immune cell subsets, which mediate IL-2 activity (Minami, 
Kono, Miyazaki, & Taniguchi, 1993). To survive and proliferate, CTLL-2 cells, which 
display the IL-2R complex, require IL-2 to interact with the IL-2 receptor. Therefore, 
CTLL-2 cells are commonly used to assess IL-2 activity/stability (Gillis & Smith, 1977). 
The reduced ability of IL-2 formulated in 30mM CDHP to trigger CTLL-2 cell 
proliferation without affecting survival may be due to modifications in the tertiary 
structure of the protein. Interestingly, ELISA data demonstrated that rhIL-2 formulated in 
buffered CDHP in NaHCO3 (pH ≥7.2) shows no signs of structural integrity disruption. 
To be detected by a sandwich ELISA, two conformational motifs have to be recognized 
by two separated monoclonal antibodies, thus providing indirect evidence of tertiary 
protein structure integrity (at least in the regions involved in this binding interaction). In 
addition, previous CD scan analysis performed on rhIL-2 formulated in CDHP (680 mM, 
pH 7.4) demonstrated no evidence of disruption of IL-2 tertiary structure. It did, however, 
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suggest some tightening of secondary structure as evidenced by an increase in α-helix and 
β-sheet content (K. D. Weaver et al., 2012). 
The loss of rhIL-2 functionality, when formulated with CDHP, could be explained 
in the context of an increase in protein thermal stability. While the parameters that define 
thermal stability (improved intramolecular hydrogen bonding, hydrophobic packing, Van 
der Waals interactions) may interact to create a more conformationally robust protein, 
they can also restrict conformational mobility to limit protein functionality (Vogt & 
Woell, 1997). To explore this further in terms of thermodynamic equilibrium, we can 
look at a protein folding and unfolding pathway as shown by EQUATION 1.  
𝑁↓𝑚𝑜𝑏𝑖𝑙𝑖𝑡𝑦 ↔ 𝑁 ↔ 𝐼 ↔ 𝑈 → 𝑈𝑖𝑟𝑟𝑒𝑣. 
𝐼 ↔ 𝐴 → 𝐴𝑖𝑟𝑟𝑒𝑣. 
EQUATION 1: Protein folding-unfolding pathways 
The native protein (N) is the correctly folded protein with full biological activity. A 
typical unfolding pathway proceeds to the right in which the protein may exist in an 
intermediate (I) or partially unfolded conformations, which can fully unfold (U) or 
aggregate (A). These unfolding and aggregation pathways may be reversible or 
irreversible (Uirrev. , Airrev.).  An increase in the thermal stability may push the 
thermodynamic equilibrium so far to the left that the native protein transitions to a more 
compact, less mobile conformation (𝑁↓𝑚𝑜𝑏𝑖𝑙𝑖𝑡𝑦). Such a conformation may result in 
altered biological activity due to decreased conformational mobility (Kendrick et al., 
1997).  
IL-2 binds to the IL-2R complex through a sequence of events. The cytokine first 
interacts with IL-2Rα through a large hydrophobic binding surface surrounded by a polar 
border, resulting in a relatively weak interaction (Kd 108 M) (Malek & Castro, 2010). The 
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IL-2Rα-IL-2 binary complex leads to a necessary conformational change in IL-2 to 
encourage association with IL-2Rβ via polar interactions, forming a ternary structure with 
intermediate stability (Kd 109 M). Finally, the complex IL-2Rα-IL-2Rβ-IL-2 complex 
then interacts with the final IL-2R subunit,  γc, through a weak interaction with IL-2 and 
a stronger interaction with IL-2Rβ to produce a stable quaternary IL-2-IL-2R complex 
(Kd 1011 M) (Gillis & Smith, 1977). This orchestrated series of events obviously requires 
a significant amount of IL-2 conformational mobility. It is possible that the interaction 
between IL-2, surrounding water molecules, and CDHP decreases the kinetic freedom of 
the protein, thus impacting the ability of IL-2 to interact with IL-2R displayed on the 
CTLL-2 cells, and decreasing the ultimate proliferation of these IL-2 dependent cells. 
The increase in IL-2 secondary structure content in the presence of CDHP that has been 
observed elsewhere (K. D. Weaver et al., 2012) supports such a hypothesis. If CDHP 
shifts the equilibrium towards the more compact N* state (EQUATION 1), full biological 
activity, which requires the fully flexible native (N) conformation, will be compromised. 
Furthermore, while our study focused on structural integrity of IL-2, we cannot rule out 
that CDHP also interferes in the assembly of the high affinity, three-unit IL-2R, 
impacting IL-2 ability to interact with CTLL-2 cells chronically exposed to CDHP. 
These data are of particular interest given that IL-2 is a relatively unstable protein 
compared to lysozyme (an antibacterial protein secreted in saliva and mucus) or 
cytochrome C (heme protein component of the mitochondrial electron transport chain), 
which are robust proteins reported to retain functionality when exposed to acidic 
conditions and reactive oxygen species (Olteanu et al., 2003; Proctor & Cunningham, 
1988). IL-2, on the other hand, is a cytokine that is physiologically secreted into the 
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buffered and thermally stable conditions of the circulation. These fundamental 
differences in the physiological roles of these three proteins may explain the higher 
functional sensitivity of IL-2 compared to lysozyme and cytochrome c despite similarities 
in molecular weight [14.7 kDa (cytochrome C), 12 kDa (lysozyme), and 15.5 kDa (IL-
2)]. Maintaining the pH at near physiologic levels was important for maintaining the 
structural integrity of IL-2. IL-2 activity losses have been observed elsewhere in acidic 
conditions due to the disruption of disulfide bond integrity (Shu-Mei Liang, 1986). 
However when IL-2-dependent cells were treated with pH controlled CDHP based 
formulations, activity levels were still reduced. 
To distinguish the interaction between CDHP and cells as opposed to IL-2 and to 
further probe the biocompatibility of CDHP, cytotoxicity of CDHP on two cell systems 
was evaluated in this work.  Our lab has previously conducted CDHP cytotoxicity assays 
upon J774 mouse macrophages to rank choline salts in order of toxicity. These studies 
established an EC50 value (effective concentration that causes cell death in 50% of the 
population after 48  hours of exposure) of 20 mM for CDHP (Katherine D. Weaver, Kim, 
Sun, MacFarlane, & Elliott, 2010). Here we also examined relative toxicity to other cell 
types (primary splenocytes and B16-F10 cells) to understand these toxic effects in greater 
detail. By maintaining a near physiological pH, cells tolerated chronic exposure (24–48 
h) to CDHP at levels ≤80 mM level, a concentration resulting in a moderately hypertonic 
solution. While these results are preliminary assessments of biocompatibility and cannot 
be directly extrapolated to predict in vivo response, the results suggest that CDHP appears 
to be as benign as other dissociating physiological salts under typical culture conditions. 
Extending toxicity testing to higher levels of chronic exposure would have resulted in 
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excessive osmotic stress to cells, and would not have revealed any further direct toxicity 
information about CDHP. These data suggest that if appropriately defined solution 
osmolarities can be achieved, there is no immediate cellular toxicity. Ideally an 
intravenously administered medication should have an osmolality near physiological 
levels (300 mOsm/L) and no more than 600 mOsm/L to prevent inflammation (Hicks & 
Becker, 2006), although there are certainly exceptions to this. Peripheral parenteral 
nutrition is often administered at levels up to 750mOsm/L, while central parenteral 
nutrition is administered up to 1400mOsm/L.  The rate of infusion must also be 
considered. For example in an in vivo experiment by Kuwahara et al. (Kuwahara, 
Asanami, & Kubo, 1998), venous epithelial cells tolerated osmolarities of 820 mOsm/kg 
for 8 h, 690 mOsm/kg for 12 h, and 550 mOsm/kg for 24 h of a nutritional solution. 
Similarly, an intramuscularly administered volume of 0.5 mL of 300–1100 mOsm/kg 
solution has been reported to be well tolerated (Nony, Girard, Chabaud , Hessel, & 
Thébault, 2001). Assuming complete dissociation of the salts used in this study, the 
osmolarities of the buffered 680mM solutions would be expected to be approximately 
3000mOsm/kg (too high to be administered parenterally without dilution or CDHP 
removal prior to administration). This is calculated based upon the measured osmolality 
of a 680mM CDHP (buffered to pH 7.4 with NaHCO3) of 1520mmol/kg, given in section 
3.3.1. By extension, a 30 and 80mM CDHP (pH ≥7.2) solution would be approximately 
130 and 350mOsm/kg. Thus the concentrations that studied in this work reveal the 
potential for achieving a beneficial protein stabilization effect at concentrations that are 
hypothetically injectable, or which could be employed in controlled releases devices. 
Depending on the osmolarity/ osmolality limitations of the chosen administration route, 
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possible in vivo administrations schemes for IL-2 formulated with CDHP are illustrated 
in FIGURE 10a-d. At CDHP concentration requiring no dilution/ removal prior to 
administration, formulations could be given according to FIGURE 10a and c. If the 
CDHP concentration results in an osmolality that is deemed not safe for the chosen 
administration route, the IL-2 CDHP formulation can be diluted prior to injection 
according to FIGURE 10c. If such a preparation is formulated within a controlled release 
device, the device may have to be engineered so as to release IL-2 and CDHP at different 
release rates so that cell and tissue exposure to CDHP maintained within appropriate 
osmolality guidelines (FIGURE 10d). 
Utilization of different cells enabled a more comprehensive understanding of the 
specific effects of CDHP on biological systems. Robust cell lines such as the B16-F10 
melanoma or J774 macrophages (R. Vrikkis et al., 2009) are transformed, immortalized 
cells capable of surviving relatively adverse conditions such as acidic pHs, limited 
nutrient availability, and pro-apoptotic signals. It is therefore not surprising that we found 
a lack of cytotoxicity for CDHP (0–80mM) on the B16-F10 cell line despite decreases in 
culture medium pH (pH<7.0). To further explore CDHP biocompatibility, we also 
performed cytotoxicity assays using primary cell cultures of freshly isolated splenocytes. 
This model presents a more physiologically relevant system (compared to immortalized 
tumor cells). Splenocytes are a mixed population of motile, spleen leucocytes that 
propagate in culture without attaching to solid surfaces. Using this splenocyte model 
system, significant cytotoxic activity was detected at levels of CDHP as low as 40mM 
when pH was not tightly regulated. However this effect could be countered by increasing 
the buffer capacity of the media with NaHCO3 supplementation, thus maintaining pH 
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near physiologic levels. Interestingly, cytotoxicity was only detectable in cultured 
splenocytes by performing direct cell counts (trypan blue exclusion assays), as data from 
metabolism-based assays (resazurin reduction) did not mirror the cell count data. Indeed, 
the metabolic resazurin reduction assays actually demonstrated what, at first analysis, 
appeared to be increased relative cell viability in the presence of CDHP (10–40mM). 
These measurements highlight a fundamental feature of metabolism-based methods of 
measuring cell viability (e.g., resazurin, MTT); early cell death events can be masked by 
increased cellular metabolism. This feature can lead to an overestimation of cell survival, 
but it also provides the opportunity to quantify cell stress via changes in metabolic 
activity following chronic exposure to non-cytotoxic (as assessed by trypan blue 
exclusion) levels of CDHP (Hashimoto et al., 2004; Takeda et al., 2002). Collectively 
these data demonstrate that at non-cytotoxic CDHP levels (0–40mM), CDHP 
significantly increased cell stress, but this can be effectively countered by increasing the 
buffer capacity with NaHCO3 to maintain a physiologic pH in the solutions. 
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3.5 Conclusions 
We had previously reported that CDHP increases the thermal stability of the 
therapeutic protein IL-2, and in this study we further investigated the applicability of 
CDHP as a stabilizing excipient for aqueous IL-2 formulations. The use of CDHP 
(pH≤7.2) allowed a better retention of IL-2 structural integrity at high temperature with 
no apparent cytotoxicity toward splenocytes and B16-F10 melanoma cells up to 80mM. 
Formulating IL-2 with CDHP (pH≤7.2) reduced its biological activity in vitro but the 
protein retained the ability to bind at two structurally relevant sites as measured by an 
FIGURE 10: Possible in vivo administration strategies for IL-2 CDHP formulations 
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ELISA. This suggests that a trade-off might be necessary between thermal stability and 
biological activity if residual CDHP is expected to be present when IL-2 binds to its 
receptor. This trade-off may be acceptable when formulations are expected to experience 
thermal excursions, such as might occur in the creation of new IL-2 delivery devices such 
as controlled release liposomes and nanoparticles. In the current study it was found that 
the kosmotropic anion, dihydrogen phosphate, provided the dominant stabilizing effect 
while the anion choice had a relatively neutral effect. This suggests further opportunity to 
optimize the cation choice in order to design solution properties that are most desirable 
for IL-2 formulation. 
 
 
 
 
 
CHAPTER 4: STABILITY OF INTERLEUKIN-2 IN A LIPID NANOPARTICLE 
ENVIRONMENT: EFFECT OF LIPID COMPOSITION 
 
 
4.1 Introduction 
Many therapeutic proteins, including interleukins, interferons, hormones, and 
enzymes are rapidly cleared or degraded within the body. As a small protein 
(<50,000kDa), IL-2 is cleared from the body via kidney filtration  and extraction 
(Gibbons, Luo, Hannon, Braeckman, & Young, 1995) or via a receptor mediated 
mechanism (Piecilelli et al., 1996). The high blood clearance rate of IL-2 (Barton-Burke, 
2006 ; Konrad et al., 1990; Rosenberg et al., 1985) necessitates a high and frequent 
dosing schedule to maintain an effective circulating therapeutic level. This dosing size 
and frequency can induce severe toxicity which often requires cessation of treatment 
(Rosenberg et al., 1987). To overcome the fast clearance rates and toxicity associated 
with systemically administered IL-2, nanoparticle carriers have been examined as a way 
to target tumor tissue and/or increase circulation time and thus improve IL-2 therapeutic 
outcome. Liposomal nanoparticles are flexible carriers in that they have the ability to 
incorporate both hydrophilic (within the aqueous interior) and hydrophobic molecules 
(within the hydrophobic bilayer), are easily manufactured, are biodegradable, and can be 
formulated with a variety of non-toxic lipids.  
One strategy to improve IL-2 therapy is to increase the circulation time of IL-2 
using liposomes.  IL-2 liposome removal from the general circulation by macrophages 
can be minimized or avoided by liposomal surface modification with hydrophilic 
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polymers. Coating with hydrophilic polymers such as PEG has been shown to decrease 
binding of serum proteins to liposomes. Binding of these serum proteins, called opsonins, 
is the first event in the removal of liposomes from circulation by macrophages 
(Immordino, Dosio, & Cattel, 2006). Such ‘stealth’ liposomes have been shown to 
increase the half-life of the circulation time for IL-2 administered intravenously by 10-30 
times compared to free IL-2 (Kedar et al., 2000).  
Another strategy to improve IL-2 therapy using liposomes is to target these 
liposome carriers to specific cells, tissues, or systems where they ultimately release their 
payload. Targeting of drugs not only maximizes the efficiency of the drug dose, but 
decreases the adverse effects associated with drug interaction with non-targeted cells and 
tissues. It is the ‘holy grail’ of many cancer studies today seeking to target local tumor 
cells while avoiding healthy tissue. Indeed, localized administration of IL-2 within the 
tumor vicinity has been shown in several studies to be more effective and less toxic than 
systemic administration. Peritumeral IL-2 injections were shown to inhibit the growth of 
experimentally induced fibrosarcoma tumors in mice by Burbenik et al, while Jacobs et al 
observed a higher survival rate in patients receiving localized administration of free IL-2 
to treat nasopharyngeal carcinoma (Bubeník, 1990; Jacobs, Sparendam, & Den Otter, 
2005).   
In addition to targeting tumor tissue, lymphatic targeting using liposomes may 
improve IL-2 immunotherapy. Such a strategy has not been studied for IL-2. The adverse 
effects of this immunotherapeutic are associated with IL-2 interaction with certain 
entities within the blood stream (namely natural killer cells and neutrophils), while the 
beneficial effects are due to the interaction of the protein with the IL-2 receptor (IL-2R) 
47 
 
expressing activated CD4+ T-cells, which reside largely in the lymphatic system 
(Caligiuri, 1993; Stites, 1994; van Haelst Pisani et al., 1991).  Furthermore, because the 
lymphatic route is one of the primary routes for tumor metastasis, lymphatic targeting of 
IL-2 is an avenue of enormous potential.  
The targeting ability and pharmacokinetics of liposomes are largely a factor of 
liposomal carrier size, administration route, and surface characteristics (charge, 
modification with hydrophilic polymers) (Gabizon, 2001; Hawley, Davis, & Illum, 1995; 
Christien Oussoren & Storm, 2001). One route in particular that has been evaluated for 
lymphatic targeting by liposome carriers is the subcutaneous route (C. Oussoren & 
Storm, 1999; Christien Oussoren & Storm, 2001; C. Oussoren et al., 1998; C. Oussoren, 
Zuidema, Crommelin, & Storm, 1997; Zuidema, Kadir, Titulaer, & Oussoren, 1994). 
Based on molecular weight, one could expect a little less than 50% of the administered 
dose of IL-2 (MW=15.4kDa) to accumulate within the lymph. The rest of the dose could 
be expected to accumulate within the blood plasma (Andreas Supersaxo, Hein, & Steffen, 
FIGURE 11: Lymphatic targeting of IL-2 using optimally sized liposomes 
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1990). Indeed, after subcutaneous administration of IL-2 to pigs, about half the injected 
dose was recovered in the lymph, while the remainder was recovered in the plasma (Chen 
et al., 2000). Particles between 10-100nm are optimally absorbed into the lymphatic 
capillaries from the subcutaneous or interstitial space, with lymphatic uptake reaching 
approximately 70% of the injected dose (Christien Oussoren & Storm, 2001). Smaller 
particles are preferentially absorbed by the blood capillaries (Andreas Supersaxo et al., 
1990; Swartz, 2001). Larger particles remain within the tissue, which can be used as to 
create a depot for a continuously released drug (Chung, Yang, & Tsai, 2006; Meyenburg, 
Lilie, Panzner, & Rudolph, 2000; S. S. Wang, Yang, & Chung, 2008). Therefore, 
liposomal carriers offer the possibility of increasing the amount of IL-2 absorption into 
the lymphatic system (FIGURE 11). 
IL-2 liposomes have been documented in literature (Bergers et al., 1993; Boni et 
al., 2001; Fleury et al., 1995; Johnston et al., 2006; Kanaoka et al., 2001, 2003; Kanaoka 
et al., 2002; Kedar et al., 2000; Kedar et al., 1994; F.J. Koppenhagen, 1997; F. J. 
Koppenhagen et al., 1998; Kulkarni et al., 1987; Neville, Boni, et al., 2000; Neville, 
Richau, et al., 2000; Pellequer et al., 2004). Most studies have attempted to increase IL-2 
encapsulation using potentially denaturing methodologies  (Bergers et al., 1993; Fleury et 
al., 1995; Johnston et al., 2006; Kulkarni et al., 1987; Neville, Boni, et al., 2000). 
Encapsulation of drugs within the interior of the liposome typically requires breaking and 
reforming the vesicles through sonication, multiple freeze/thaw cycle, or extrusion of the 
lipid-drug mixture, exposing the drug molecule to mechanical stress and elevated 
temperatures (at least 10˚C above the phase transition temperature of the lipid). These 
strategies are less of a concern for small molecule drugs with no secondary structure, but 
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protein drugs are sensitive to thermal and mechanical denaturation. The ability to 
mitigate or avoid these stresses is of paramount importance for fragile and often 
expensive protein drugs, such as IL-2. Adsorption of IL-2 to preformed liposomes allows 
one to bypassing thermal stress and mechanical stress. Because IL-2 undergoes 
irreversible thermal denaturation (Foureau et al., 2012; K. D. Weaver et al., 2012), 
avoidance of thermal stress during the formulation of an IL-2 liposome carrier is 
desirable. (Foureau et al., 2012; Pellequer et al., 2004; K. D. Weaver et al., 2012). 
Several authors have noted IL-2 association with the lipid bilayer, even when 
traditional encapsulation methods are employed (Bergers et al., 1993; F. J. Koppenhagen 
et al., 1998; Neville, Boni, et al., 2000). Neville et al observed bulges within DPPC 
liposome lamellae in IL-2 containing liposomes indicating intercalation of the protein 
using electron microscopy. IL-2 was also observed on the surface as indicated by the 
ability of IL-2 to bind to an anti-IL-2 antibody (Neville, Boni, et al., 2000). Bergers et al 
was able to modulate IL-2 incorporation efficiency into PC:PG (9:1) liposomes by 
modulating pH and ionic strength in order to maximize electrostatic interaction between 
the liposome surface and IL-2. They concluded that since this result could not be 
explained by differences within the aqueous interior space, IL-2 must associate with the 
bilayer, although the extent of hydrophobic as compared to electrostatic interaction was 
not investigated (Bergers et al., 1993). Koppenhagen et al also found evidence for IL-2 
lipid bilayer association. When IL-2 was added to preformed DPPC liposomes, the steady 
state fluorescence of IL-2 increased, indicating changes in the microenvironment of IL-
2’s tryptophan residue (F. J. Koppenhagen et al., 1998). Only one study has probed the 
effect of modulating lipid acyl chain length on IL-2 interaction with lipid bilayers. 
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Kanaoka et al adsorbed IL-2 to preformed DMPC (12 carbons in the acyl chain), DPPC 
(14 carbons), DSPC (16 carbons) liposomes, and found the highest incorporation 
efficiency for DSPC. All these liposomes are neutrally charged, and the effect of 
including a negatively charged lipid was investigated by incorporating IL-2 into 
DSPC:DSPG (10:1 molar ratio) liposomes. The incorporation efficiency for DSPC:DSPG 
(10:1) liposomes was similar to that of DSPC liposomes. These incorporation efficiencies 
were evaluated by comparing the amount of free IL-2 versus bound IL-2 after separation 
of these two populations via gel filtration chromoatography. (Kanaoka et al., 2001). 
While the similar IL-2 incorporation ratios seen for DSPC and DSPC:DSPG liposomes 
suggested a hydrophobic interaction rather than electrostatic association, the exact nature 
of this interaction was explored.  
Although IL-2 association with lipid bilayers has been observed and assumptions 
on the nature of this interaction (whether the interaction is governed by hydrophobic 
versus electrostatic) have been made on the basis of incorporation efficiencies upon 
modulation of pH, ionic strength  (Bergers et al., 1993), and liposome lipid composition 
(Kanaoka et al., 2001), the thermodynamics of this interaction have not been specifically 
characterized. It is apparent that lipid choice affects IL-2 interaction with the liposome 
carrier (Kanaoka et al., 2001). However, no study has been performed comparing IL-2 
release kinetics from its liposomal carrier and bioactivity the released protein as a 
function of liposome composition. Thus the relationship between liposome composition, 
binding and release thermodynamics or kinetics, and the subsequent functionality cannot 
be established given current literature. Because design of controlled release drug delivery 
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constructs requires the optimization of release kinetic behavior as well as the release of a 
functional product, these relationships are of clinical concern.  
Another parameter that has been largely ignored in the formulation of IL-2 
adsorbed to liposomes is the potential for change in the size distribution upon IL-2 
incorporation. Because of its proclivity to associate with lipid bilayers, a size increase 
would be expected. Size, which affects diffusion and absorption of liposomes between 
cells, tissues, and systems in vivo, is therapeutically relevant for targeting purposes (C. 
Oussoren et al., 1997).  
To avoid the thermal and mechanical stresses accompanying traditional 
encapsulation methods, this study will adsorb IL-2 to preformed liposomes. The 
simplicity of such a preparation may translate to cost effective scale up production. 
Adsorption of IL-2 to preformed liposomes is possible due to the amphiphilicity of IL-2, 
which contains regions of hydrophobicity and hydrophilicity. The majority of the protein 
contains regions of hydrophobicity (Christoph Alexander Bergmann, 1991), which may 
have a proclivity to associate with the hydrophobic lipid bilayer. In addition to 
hydrophobic interaction between IL-2 and the lipid bilayer, electrostatic interactions may 
be involved in adsorption of IL-2 to the bilayer. Electrostatic interaction may serve as the 
primary interaction between the protein and liposome, or may also be a precursor to 
further adsorption into the lipid acyl chain region for proteins with more hydrophobic 
regions (Norde, 1996).  
We hypothesize that predominantly hydrophobic proteins will likely associate 
with the hydrophobic acyl chains of a lipid bilayer. Therefore the choice of lipids with 
longer acyl chains will exploit this interaction. Here we investigate three saturated 
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phosphatidylcholine based lipids with acyl chain lengths of 14, 16, and 18 carbons. These 
lipids are 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC), and 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC), respectively. These lipids carry an overall neutral charge at pH 7.4. 
Phosphatidylcholine is a major part of biological cell membranes, is non-toxic, and is one 
of the most common lipid types used in pharmaceutical liposome formulations. 
The size of IL-2 makes it likely that the protein will not fit completely within this 
acyl chain region (Cornell & Separovic, 1983; Lewis & Engelman, 1983; Rickert, Wang, 
Boulanger, Goriatcheva, & Garcia, 2005), and at least some portion of the protein will be 
in close proximity to the phospholipid head groups of the lipid. Hence it is foreseeable 
that IL-2 association with lipid bilayers can be modulated by increasing the acyl chain 
length and head group interaction. Several studies have employed this strategy, and 
successfully adsorbed IL-2 onto preformed liposomes containing  PC and PG head 
groups, which results in a lipid bilayer with a negative charge (-1) at physiological pH 
(Kanaoka et al., 2001, 2003; Kanaoka et al., 2002; F. J. Koppenhagen et al., 1998). The 
predominant mechanism of interaction was not directly probed in these studies, and the 
advantage of including a charged lipid head group, phosphatidylglycerol (PG), in the 
formulation rather than using only neutrally charge lipids was not readily apparent. 
Presumably the choice was made, not on the basis of IL-2 liposome interaction, but 
interaction between liposomes themselves. Negatively charged lipids such as PG are 
traditionally included in formulations to discourage liposome aggregation, and thus 
increase colloidal stability, through electrostatic repulsion. While cationic liposomes 
resist aggregation as well, they are typically used to neutralize and carry negatively 
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charged DNA (Escobar-Chávez, 2010), and are limited in their use due to instability, 
rapid clearance, and toxicity (Immordino et al., 2006). In this work, we have included 
1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DSPG) to assess the effect of a 
negative charge on IL-2 lipid interaction as well as liposome aggregation phenomena. 
In this work we provide a fundamental understanding of IL-2 lipid bilayer 
interaction by systematically evaluating the effect of lipid acyl chain length and lipid 
bilayer charge on the strength and nature of IL-2 liposome interaction, the release kinetics 
of IL-2 from the vesicle, and the implications on protein stability. Because protein 
stability is of utmost concern to maintain a therapeutically effective drug, the thermal and 
mechanical stresses associated with encapsulation methods have been avoided, and 
adsorption to preformed liposomes employed. Understanding the nature of IL-2 liposome 
interaction and the pharmaceutical implications (such as the release rate of IL-2 from the 
carrier and its subsequent bioactivity) will improve the rational design of IL-2 liposome 
drug delivery constructs.  
4.2 Materials and Methods 
4.2.1 Materials 
4.2.2 Liposome Preparation 
Liposomes composed of DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), 
DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DSPC (1,2-distearoyl-sn-glycero-
3-phosphocholine), and DSPC (1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol)) 
were prepared from lipid powder or chloroform suspensions. Chloroform was removed 
from lipid suspensions by evaporation under argon gas. The resultant lipid powder was 
dissolved in water, heated to at least 10˚C above the phase transition temperature of the 
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lipid, and allowed to solubilize for at least an hour. The suspensions were vortexed with 
2-3 glass beads of 1mm diameter for several seconds to create a heterogeneous 
suspension of multilamelar liposomes (MLVs). The heated liposome suspension was 
passed through a polycarbonate filter with 100nm sized pores at least 21 times using a 
MiniExtruder from Avanti Polar Lipids, Inc (Alabaster, AL). The resultant 100nm 
unilamellar liposome suspension was stored at 4˚C overnight before use. All liposome 
concentrations are given as lipid concentrations. 
4.2.3 Determination of Binding Constants, Stoichiometric Ratios, and Enthalpic and 
Entropic Contributions to Binding 
The binding constants of IL-2 interaction with the liposomal bilayer were 
monitored with NanoITC and analyzed with NanoAnalyze software (TA Instruments, 
Lindon, UT). In addition to the binding constants, the data from these experiments were 
also used to determine the optimal stoichiometric ratios of IL-2 to lipid as a function of 
lipid composition within liposomes. These protein:lipid ratios were later used to optimize 
the concentration of IL-2 to adsorb IL-2 to preformed liposomes before evaluation of 
release kinetics, bioactivity, and liposome size and melting transition thermodynamics.  
The Nano ITC used in this study employs a differential power compensation, 
which measures the change in power needed (μJ/s) required to maintain the system at a 
constant temperature. In all experiments, an IL-2 solution was contained within 
calorimeter cell and the lipid vesicles were injected at discrete intervals via a titration 
syringe. Shown in FIGURE 12a and b are (a) typical raw data and (b) integrated titration 
curves fitted to a multiple independent binding site model during an isothermal titration 
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calorimetry experiment. 
 
FIGURE 12: Typical isothermal calorimetric titration of liposome into IL-2 solution. Here a 20mM DPPC is injected in 
5μl intervals into 300μL 15μM IL-2 at 37˚C (a) Raw data showing power compensation required by ITC to maintain 
constant temperature as each titration results in a binding event (NOTE: exothermic event shown here with peaks 
pointing up) (b) Integration of raw data,  subtraction of the appropriate blank experiment (liposomes into water only to 
account for heat due to dilution) , and fitting with a non-linear regression technique allows determination of enthalpy 
change and stoichiometry of binding reaction. 
 
During the initial titration, all of the injected liposomes bind to the protein. As the 
lipid titrations continue, free IL-2 becomes bound to lipid molecules and is removed from 
the bulk solution, leaving less protein available for binding.  This is evidenced by a 
decrease in binding reaction enthalpy as lipid titrations continue (FIGURE 12a). At the 
end of the titration sequence, all binding sites are saturated and no heat other than the 
heat of dilution is observed. A blank experiment is run with an identical liposome into 
water scan to measure the heat of dilution (not shown). The area under these peaks, 
which is equal to the enthalpy change, is calculated and plotted as a function of the molar 
ratio of lipid to protein. Shown is a typical binding reaction fit with an independent 
binding site model, which assumes all binding reactions can be described by the same 
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binding constant and each binding event is independent of one another (FIGURE 12b). 
The overall enthalpy change, ΔH, of the event is given on the y-axis and the lipid to 
protein ratio is given on the x-axis. 
The sigmoidal shape of the titration curve is consistent with an independent 
binding site model, which assumes that each individual binding site on the 
macromolecule (IL-2, in this case) is independent of all other binding sites. The equations 
used to fit this integrated titration data are obtained from algebraic manipulations of 
fundamental chemical thermodynamic relationships.  
It was assumed that free IL-2 (𝐼𝐿_2) and lipids within an empty, preformed 
liposome (𝐿𝑖𝑝𝑖𝑑) bind to form an IL-2 lipid (liposome) complex (𝐼𝐿2_𝐿𝑖𝑝𝑖𝑑) according 
to EQUATION 2. 
𝐼𝐿2 + 𝐿𝑖𝑝𝑖𝑑
𝐾𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛
⇌
𝐾𝑑𝑖𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛
𝐼𝐿2_𝐿𝑖𝑝𝑖𝑑  
EQUATION 2: Binding equilibrium reaction 
 The binding constant, Kassociation, is defined as in EQUATION 3, where the brackets indicate 
molar concentrations. The binding constant is the inverse of the dissociation constant, Kdissociation. 
It stands to note that this binding constant (between IL-2 and lipid within a liposome) can be 
expected to be different for IL-2 bound to free lipid, because lipids within the inner bilayer leaflet 
of the liposome may not be available for binding.  
𝐾𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛 =
[𝐼𝐿2_𝐿𝑖𝑝𝑖𝑑]
[𝐼𝐿2][𝐿𝑖𝑝𝑖𝑑]
= (𝐾𝑑𝑖𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛)−1 
EQUATION 3: Binding and dissociation constant 
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As the titrations continue, the concentrations of the IL-2 lipid complex, free IL-2, 
and free lipid constantly change, but the ratio of Kassociation does not. Now let us define 
two constants in terms of these changing concentrations. 
𝐶𝐿𝑖𝑝𝑖𝑑 = [𝐿𝑖𝑝𝑖𝑑] + 𝑛[𝐼𝐿2_𝐿𝑖𝑝𝑖𝑑] 
EQUATION 4 
𝐶𝐼𝐿_2 = [𝐼𝐿_2] + [𝐼𝐿2_𝐿𝑖𝑝𝑖𝑑] 
EQUATION 5 
 The two variables, CLipid and CIL_2, are constants, known from the initial concentrations 
of the protein and empty liposomes at time zero.  The stoichiometry, n, is the number of 
binding sites on the IL-2 molecule that bind with each lipid molecule. In other words, for 
a single IL-2 molecule, there are ‘n’ number of lipids involved in the binding reaction. If 
EQUATION 4 and EQUATION 5 into EQUATION 3 are combined, we can solve for 
[IL2_Lipid], which takes the form of an algebraic quadratic equation in which 
b=�𝑛𝐶𝐿𝑖𝑝𝑖𝑑𝐾𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛 + 𝐶𝐼𝐿_2𝐾𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛 + 1�. 
[𝐼𝐿2_𝐿𝑖𝑝𝑖𝑑] =
𝑏−�(𝑏)2−4𝑛𝐾𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛
2 𝐶𝐿𝑖𝑝𝑖𝑑𝐶𝐼𝐿_2
2𝑛𝐾𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛
 
EQUATION 6 
Now we turn to the parameter, n. The heat or energy of the reaction, Δq, can be 
defined in terms of the total change in enthalpy, ΔH.  
∆𝑞
(𝑛∆[𝐼𝐿2_𝐿𝑖𝑝𝑖𝑑]∆𝑉𝑐𝑒𝑙𝑙)
= ∆𝐻 
EQUATION 7 
In EQUATION 7, the quantity 𝑛∆[𝐼𝐿2_𝐿𝑖𝑝𝑖𝑑] represents the concentration of the 
complex in units of moles per volume, while the term ∆𝑉𝑐𝑒𝑙𝑙 represents the volume 
58 
 
change within the cell as a result of the titrations and binding reaction. This equation is 
combined with EQUATION 6 and fit to minimize the error of Kassociation, n, and ΔH.  
Once Kassociation, n, and ΔH have been determined, one can easily solve for the 
Gibbs free energy change and the entropic contribution to binding. R and T represent the 
gas constant and temperature, respectively.  
∆𝐺 = −𝑅𝑇𝑙𝑛𝐾𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛 = ∆𝐻 − 𝑇∆𝑆 
EQUATION 8: Gibbs free energy equation of binding reaction 
The enthalpy (ΔH) and entropy 
(ΔS) contributions to binding can be 
used here as an indication of the nature 
of IL-2 lipid interaction. The insertion of 
a protein into a lipid bilayer may be 
enthalpy (ΔH) driven, and influenced by 
electrostatic interactions, H-bonds, or 
van der Waals interactions (short, 
attractive forces between neighboring 
acyl chains). Interaction between IL-2 and the liposome may also be driven by 
hydrophobic interactions between the protein and water molecules, an entropy (ΔS) 
driven phenomenon. An increase in the system entropy (as defined by the boundaries of 
the calorimeter cell in which the reaction is taking place) arises due to the elimination of 
orderly, clathrate water structures around a hydrophobic protein as a hydrophobic protein 
penetrates into the lipid bilayer  (Tanford, 1980) (FIGURE 13). 
FIGURE 13: Entropic contribution to IL-2 liposome 
interaction. Left: Because IL-2 is a hydrophobic molecule, 
water molecules preferentially interact with one another 
than IL-2. Water molecules surround free IL-2 in an 
organized clathrate formation. This corresponds to a lower 
system entropy. Right: As IL-2 is incorporated into the 
liposome and removed from the aqueous environment, 
these organized clathrate cages are broken, corresponding 
to a higher system entropy.   
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All binding constants and reaction enthalpies were measured by lipid into peptide 
titrations. Liposome solutions (0-200mM lipid solution) were degassed by vacuum and 
injected in aliquots of 2-10ul into the sample cell, where 300ul of a degassed 6.54-15uM 
solution of IL2 was present. Protein and liposome solution concentrations and injection 
volumes were optimized in order to obtain the entire binding curve. All titrations were 
performed in triplicate. 
4.2.4 Preparation of IL-2 Liposomes 
4.2.4.1 Adsorption of IL-2 to Preformed Liposomes 
IL-2 was adsorbed onto preformed liposomes in the following manner.  The 
protein was added to the liposome suspension at an IL-2:lipid molar ratio, n, as defined 
and determined within the isothermal calorimetry experiments. These suspensions were 
gently mixed and incubated at 4˚C for 30 minutes. It has been shown in literature that 
incubation time has a minimal effect on the amount of IL-2 incorporated in liposome, and 
that 30minutes was a sufficient amount of time for IL-2 to adsorb into lipid bilayers (F. J. 
Koppenhagen et al., 1998) . 
FIGURE 14: Separation of free and bound IL-2 from liposomes prior to analysis 
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4.2.4.2 Separation of Free and Bound IL-2 
To ensure all free IL-2 not adsorbed to preformed liposomes after incubation was 
removed prior to evaluation of in vitro IL-2 release kinetics, IL-2 liposome size 
distribution and melting transition thermodynamics, or bioactivity evaluation of released 
IL-2, free and liposome bound IL-2 were separated by a Ficoll gradient method as in 
(Weissig, 1993). A comparison of the various separation methods available to separate 
free and unbound drug from liposome particles in a study by Dipali et al found that this 
method was a cost effective, rapid separation method with optimal sample recovery  
(Dipali, Kulkarni, & Betageri, 1996).  The method protocol was as follows. A layered 
suspension of a 100ul IL-2 liposome suspension, 200ul 20% w/w Ficoll in water, 1ml 
10% w/w Ficoll in water, and 100ul water was prepared in a 2ml centrifuge tube. The 
layered suspension was spun at 5000F for 1hr on a Thermo Scientific IEC Micromax FR 
Centrifuge. The IL-2 bound to liposomes partitioned in the top 100ul, and was carefully 
removed for further analysis. To confirm molar ratios of protein to lipid obtained by 
isothermal titration calorimetry, the bottom 100ul (where unbound IL-2 partitioned after 
centrifugation) was recovered. Protein concentration was quantified by a BCA assay and 
A280nm.  
4.2.5 Protein Localization in Liposome by Evaluation of Alteration of Thermotropic 
Melting Transition of Liposomes Upon IL-2 Incorporation  
Differential scanning calorimetry is one method used to detect changes to the 
melting phase transition behavior of lipid bilayers (Demetzos, 2008) as a function of 
protein and small solute molecule incorporation (Lo & Rahman, 1995). At lower 
temperatures, lipids exist in an ordered gel state in which all the rigid, extended acyl 
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chains are in an all trans-configuration. As the temperature is raised to the main transition 
temperature of the lipids (Tm), the lipids enter a disordered liquid crystalline phase in 
which more gauche conformations are present and more intra and intermolecular motions 
occur. The approach to Tm is marked by an increase in the specific heat capacity (Cp) of 
the lipid. The integrated area under the peak defined by Cp(T) within the range of the 
onset and completion temperatures defines the calorimetric enthalpy change, ΔHcal. The 
onset and completion temperatures were chosen at the intersection of the tangents to the 
baseline and the rising portion of the peak. The width of the peak at the half height, 
ΔT1/2, indicates the sharpness or cooperativity of the peak. Perturbations in these 
parameters upon protein interaction may indicate insertion or incorporation of the protein 
into the bilayer. The electrostatic or hydrophobic interactions within some protein-lipid 
systems can cause alterations in this phase transition. Papahadjopoulos et al have 
classified proteins in three categories based upon their effects on this melting phase 
transition of phospholipids. Category 1 proteins are hydrophilic and adsorb into the 
bilayer surface through electrostatic interaction. Category 2 proteins are also adsorbed 
onto the surface through electrostatic interaction, but are partially imbedded into the 
bilayer through hydrophobic interaction. Category 3 proteins penetrate into the core of 
lipid bilayers through predominately hydrophobic interaction  (Papahadjopoulos et al., 
1975). Characterization of how this interaction alters the thermodynamic parameters of 
melting (enthalpy change, Tm, or the ΔT1/2) can provide insight into where a protein is 
localized in a lipid bilayer in some cases (Demetzos, 2008). Observations observed in 
literature are shown in TABLE 1. The nature and extent of these perturbations upon IL-2 
incorporation are probed here. 
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Differential scanning calorimetry (DSC) was performed using a MicroCal VP-
DSC system (GE Healthcare). Data was analyzed using Origin software. All samples 
were degassed prior to use. The scanning rate was set to 1˚C/minute. The enthalpy 
change, Tm, or the ΔT1/2 of the melting phase transition of liposome suspensions 
(0.3mM-1mM) prior to and after IL-2 adsorption were determined. Free IL-2 was 
removed from the IL-2 liposome suspension prior to analysis using a Ficoll separation 
gradient method.  
4.2.5.2 Determination of Total Phosphorous 
The accuracy of the enthalpy change measured by DSC is dependent on the 
accuracy of lipid concentration. Inaccurate estimation of liposome (lipid) concentrations 
can result from pipetting error, weighing error, or lipid loss during the extrusion process. 
To confirm liposome concentrations prior to DSC, the total phosphorous concentration 
was analyzed using the Bartlett assay (Chen, Toribara, & Warner, 1956; Fiske & 
Subbarow, 1925). All reagent solutions were prepared using deionized water. Briefly, 
~0.1μmoles of each sample (empty liposomes and IL-2 liposomes) was placed on the 
bottom of a borosilicate glass tube, and all solvent removed under an argon stream. A 
standard curve of 0-0.228μmoles (0-350μl) was prepared from a 0.65mM phosphorous 
TABLE 1: Alteration of thermodynamic parameters of the lipid melting phase transition upon protein interaction. ↔ 
indicates no change, ↕ indicates an decrease at low protein:lipid ratios and an increase at higher ratios, ↓ indicates an 
increase, ↑indicates a decrease, and n.e. indicates that this parameter was not evaluated.  *Data from (Demetzos, 
2008; Papahadjopoulos, Moscarello, Eylar, & Isac, 1975), **Data from (Boggs, Wood, Moscarello, & 
Papahadjopoulos, 1977) 
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standard (Sigma-Aldrich, St. Louis, MO). Several boiling stones were added to each tube, 
a glass marble placed on the top to the tubes, and solutions were heated with 450μl 8.9N 
H2SO4 (Thermo Fisher Scientific, Rockford, IL) in a fume hood to 200-215˚C for 20-
25minutes in a dry bath incubator (Thermo Fisher Scientific). Tubes were cooled to 
ambient temperature for 5 minutes, 150ul H2O2 added, and heated for 30minutes at 200-
215˚C . Tubes were removed from heat and cooled for 5 minutes. A volume of 3.9ml 
distilled water and 0.5ml 2.5% (wt/vol) ammonium molybdate (VI) tetrahydrate (Sigma 
Aldrich) solution were added to each tube and mixed thoroughly. Next, 0.5ml 10% 
(wt/vol) were then added and thoroughly mixed. Tubes were covered with a marble, 
heated to 100˚C for seven minutes, and cooled. Absorbance of samples was read at 
820nm. 
4.2.6 Evaluation of Liposome Swelling and Aggregation Upon IL-2 Adsorption by 
Dynamic Light Scattering 
Because size is an important parameter governing pharmacokinetics of 
nanoparticle drug carriers, alteration in the particle size due to swelling or aggregation 
was evaluated. Dynamic light scattering (DLS) is a method that can be used to determine 
the size distribution of particles in suspension. As laser light hits these particles, a time 
dependent fluctuation in Rayleigh scattering can be observed. These fluctuations occur 
because the distance between particles, which are in Brownian motion, are changing. A 
second order autocorrelation function (𝐶(𝜏)) is generated to quantify these fluctuations.  
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𝐶(𝜏) = 𝐴𝑒−2Γ𝜏 + 𝐵 
EQUATION 9 
Γ = 𝑞2𝐷 
EQUATION 10 
Here A and B are constants, τ is the delay time, and Γ is a function of the 
diffusion coefficient, D, and the scattering vector, q, which is dependent on the scattering 
angle, refractive index, and laser wavelength. A non-linear fitting algorithm can be used 
to fit this measured function, which can then be used to obtain a diffusion constant, D. 
The diffusion constant is related to the radius of a diffusing sphere as described by the 
Stokes Einstein equation, which defines the diffusion constant as a function of the 
Boltzmann’s constant (kB), temperature (T), solvent viscosity (η), and particle diameter 
(d).   
𝐷 =
𝑘𝐵𝑇
3𝜋𝜂𝑑
 
EQUATION 11 
 Particle size before and after IL-2 incorporation was studied using dynamic light 
scattering using a 90Plus Particle Size Analyzer (Brookhaven Instruments Corporation, 
Holtsville, NY) at a fixed scattering angle of 90˚ and a temperature 25˚C. The particle 
size distribution was obtained using ZetaPlus Particle Sizing software provided by 
Brookhaven Instruments. Free IL-2 was removed from liposome suspensions 
immediately prior to analysis by the Ficoll separation method.  
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4.2.7 In Vitro IL-2 Release Kinetics From Liposome 
 
FIGURE 15: Evaluation of IL-2 release from liposomes in vitro 
 
Release kinetics of bound IL-2 from the liposome were monitored by a sample 
and replace dialysis technique, as recommended in (D'Souza & DeLuca, 2006). Release 
kinetics of IL-2 from liposomes were monitored as shown in FIGURE 15. Prior to 
evaluation of IL-2 release from liposomes, free IL-2 was removed with a Ficoll 
separation gradient method. A volume of 100ul of a sample IL-2 liposome solution was 
placed in a presoaked Slide-A-Lyzer MINI dialysis device with a MWCO of 20kDa 
(Thermo Fisher Scientific Inc, Rockford, IL) which was then placed in 1.5ml centrifuge 
tube (reservoir) with approximately 1000ul water. All release kinetics were performed at 
37˚C to mimic temperature conditions in the body. The molecular weight cutoff 
(MWCO) was chosen such that liposomes and protein bound to liposomes would remain 
in the dialysis unit, but free, released protein could pass through the dialysis filter into the 
reservoir. A stir bar, rotated a medium-low speed, was placed in the bottom of the 
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centrifuge tube (the reservoir) to provide continuous agitation. All water was removed 
from the reservoir at hourly intervals for testing, and an equal volume of fresh water was 
replaced in the reservoir at each testing interval. This sample and replace dialysis method 
was continued for 6 hours. During the next 18 hours, the dialysis release kinetic 
experiment was continued without removing water from the reservoir. At the end of 18 
hours (24 hours total), free protein was removed from the reservoir and protein 
concentration quantified. 
4.2.10 Bioactivity of Released IL-2 
 To assess whether released IL-2 was still biologically active after its release from 
liposomes, IL-2 liposomes were prepared as detailed in section 4.2.4. Free IL-2 was 
removed as previously described. IL-2 was released from liposomes and separated by a 
dialysis technique by a similar method as described in section 4.2.7. 100ul of the sample 
IL-2 liposome solution was placed in a presoaked Slide-A-Lyzer MINI dialysis device 
with a MWCO of 20kDa (Thermo Fisher Scientific Inc, Rockford, IL) which was then 
placed in 1.5ml centrifuge tube (reservoir) with approximately 1000ul water. Dialysis 
was performed at 4˚C to preserve maximum protein bioactivity during the release. IL-2 
was allowed to dialyze for approximately 24 hours. A stir bar, rotated a medium-low 
speed, was placed in the bottom of the centrifuge tube (the reservoir) to provide 
continuous agitation. A control sample of IL-2 only was placed in an identical reservoir 
tube with a stir bar during the dialysis to account for any bioactivity losses due to 
incubation or stirring.  
 The total amount of IL-2 released from liposomes after this 24 hour dialysis period was 
quantified according to section 2.2.2. All samples were diluted to 120μg/μl. This total 
67 
 
(folded and unfolded) IL-2 concentration was chosen as it represents the required 
concentration of control IL-2 (after 24 hours at 4˚C under constant agitation by a rotating 
stir bar) to induce optimal growth and viability of the IL-2 dependent cell line, CTLL-2. 
The ability of IL-2 to promote CTLL-2 survival and proliferation, used as an indicator of 
IL-2 bioactivity retention, was evaluated using flow cytometry as previously described 
(see section 2.2.4).     
4.3 Results 
4.3.1 Determination of Binding Constants, Stoichiometric Ratios, and Enthalpic and 
Entropic Contributions to Binding 
Isothermal titration calorimetry (ITC) was used to determine the thermodynamic 
parameters of IL-2 binding to neutrally charged lipid membranes of various acyl chain 
lengths (14, 16, and 18 carbon chains corresponding to DMPC, DPPC, and DSPC, 
respectively). The effect of lipid charge was investigated by evaluating liposomes 
composed of DSPC:DSPG (10:1 molar ratio). This formulation was composed of lipids 
(DSPC and DSPG) with an 18 carbon acyl chain, and had an overall negative charge of (-
1) due to the inclusion of DSPG. ITC experiments were set up so that liposome solutions 
were injected into an IL-2 peptide solution, resulting in an exothermic binding reaction. 
Concentrations and injection volumes were chosen so as to observe the entire isothermal 
biding reaction curve. 
All binding isotherms in these experiments follow a sigmoidal shape when the 
lipid :IL-2 molar ratio is plotted on the x-axis and the enthalpy of binding is plotted on 
the y-axis as shown in FIGURE 12. Such a shape is consistent when binding receptor 
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sites are equivalent and independent of one another, thus supporting a multiple 
independent binding site model. 
  
 
FIGURE 16: Molar ratio of IL-2 to lipids in liposome composed of DMPC, DPPC, DSPC, and DSPC:DSPG (10:1 
molar ratio). Reported values are given as the average ± SEM.  n=3. *:p<0.05; **:p<0.01, ***:p<0.001. Statistical 
differences between lipid compositions are reported with connecting lines. 
 
 
 
The molar ratios of IL-2 to lipid within liposomes of different lipid compositions 
were determined. For a liposome into protein titration (as performed here), the lipid: 
protein molar ratio is traditionally obtained as in FIGURE 12b.  We have chosen to report 
protein: lipid ratios for ease of comparison with other IL-2 liposomes in literature, which 
typically report protein: lipid molar ratios. The molar ratio of IL-2 to protein molecules 
increased with lipid acyl chain length (0.0005:1±0.000048 for DMPC, 0.012:1±0.002 for 
DPPC, and 0.083:1±0.004 for DSPC) as seen in FIGURE 16. A statistical difference was 
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seen between DMPC and DPPC (P<0.05), DMPC and DSPC (P<0.001), and DPPC and 
DSPC (P<0.001). The inclusion of a negatively charged lipid head group with an 
identical acyl chain length in the DSPC:DSPG (10:1) formulation decreased the amount 
of IL-2 absorbed into the bilayer  from 0.083 moles IL-2 per mole lipid to 0.052±0.00033 
moles IL-2 per mole lipid (P<0.001). Thus, both lipid acyl chain length and charge 
impacted the amount of IL-2 incorporated into liposome formulations.  
 
FIGURE 17: (a) Binding constants and (b) Gibbs free energy change upon binding of IL-2 to liposomes composed of 
DMPC, DPPC, DSPC, and DSPC:DSPG (10:1 molar ratio). Reported values are given as the average ± SEM. n=3, *: 
p<0.05; **:p<0.01. . Statistical differences between lipid compositions are reported with connecting lines. 
 
  
Binding constant between lipids within liposomes and IL-2 were also assessed. 
FIGURE 17a illustrates the dependence of the binding or association constant (Kassociation, 
M-1) of IL-2 to lipid membranes on the acyl chain length of the lipids employed. This 
binding constant is defined by EQUATION 3, and represents the probability of the 
formation of a bound IL-2 lipid complex within a liposome.  There is no statistical 
difference between the binding constant of IL-2 to DMPC and DPPC. However, there is a 
significant difference (P<0.05) between the binding constant of IL-2 to DMPC and DSPC 
(Ka=1.5E 3± 3E2 M-1 and 1.9E6 ±6.9E5 M-1, respectively) and between DPPC and 
DSPC (Ka=7.7E 3±1.3E3 M-1 and 1.9E6±6.9E5 M-1, respectively). Incorporation of a 
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negatively charged lipid does not lead to a statistically significant difference in the 
binding constant (DSPC:DSPG Kb=1.4E6 ± 6.9E5 M-1) when compared to DSPC alone. 
These data show that the binding constant of IL-2 to liposomes is primarily dependent on 
lipid acyl chain length as compared to the inclusion of a negatively charged lipid. 
To further illustrate the dependence of IL-2 binding to lipids within a liposome on 
lipid acyl chain length, the favorability of the binding reaction, as given by the Gibbs free 
energy change (ΔG), was also obtained. FIGURE 17b shows the increase in ΔG at 37˚C 
upon binding of IL-2 to DMPC (ΔG= -21.713±2.523 kJ/mol), DPPC (ΔG= -
25.837±2.538 kJ/mol), and DSPC (ΔG= -39.842±2.33 kJ/mol). A more negative ΔG 
value indicates a more favorable binding reaction. A statistical difference between 
thermodynamic favorability of binding at 37˚C is seen between DMPC and DSPC 
(P<0.01) and DPPC and DSPC (P<0.05). No significant difference is seen between DSPC 
and DSPC:DSPG (DSPC:DSPG ΔG= -33.692±3.63 kJ/mol). 
Finally, the contribution of electrostatic versus hydrophobic forces to the binding 
reaction was probed and calculated according to EQUATION 8. FIGURE 18 shows the 
entropy (ΔS) and enthalpy (ΔH) contributions to binding between IL-2 and the lipid 
membrane. The entropic driving force behind this binding event increases as the acyl 
chain length increases in the number of carbons (TΔS is equal to 21.7±2.52 kJ/mol for 
DMPC, 25.59±2.576 kJ/mol for DPPC, and 33.4942.281 J/mol for DSPC). A statistically 
significant difference is seen between DMPC and DSPC (P<0.01) and DPPC and DSPC 
(P<0.05). No significant difference with regards to entropic contribution to binding is 
seen upon the incorporation of a negatively charged lipid head group (TΔS is equal to 
33.494±3.544 kJ/mol for DSPC:DSPG (10:1)). Enthalpy change upon IL-2 incorporation 
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into lipid membranes increases with acyl chain length, although this change is only 
statistically significant between DMPC (ΔH=-0.012±0.003 kJ/mol) and DSPC (ΔH=-
0.348±0.111 kJ/mol) (P<0.05). No statistical significance is seen upon incorporation of a 
negatively charged PG head group (ΔH = -0.197±0.087 kJ/mol).These data reflect that 
the driving force behind IL-2 liposome binding interaction is hydrophobic in nature for 
all lipid compositions tested. 
 
 
FIGURE 18: (a) Entropy (TΔS) and (b) enthalpy (ΔH) changes of upon IL-2 binding to liposomes composed of DMPC, 
DPPC, DSPC, and DSPC:DSPG (10:1 molar ratio). Experiments were performed at 37˚C. Values are reported as an 
average ±SEM. n=3, *: p<0.05; **:p<0.01.  . Statistical differences between lipid compositions are reported with 
connecting lines. 
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4.3.3 Protein Localization in Liposome by Evaluation of Alteration of Thermotropic 
Melting Transition of Liposomes Upon IL-2 Incorporation: Effect of Liposome 
Composition  
 
TABLE 2: Thermodynamic parameters of liposome melting phase transition prior to and after IL-2 incorporation. Data 
are expressed as averages ± SEM. n=3. Statistical differences are indicated between ‘Liposome Only’ and ‘IL-2 
Liposome’ of the same formulation. *:p<0.05, **:p<0.01. 
 
The transition temperatures and enthalpies of the IL-2 free liposomes studied here 
fall within 10-30% enthalpy change values for DMPC, DPPC, and DSPCseen in literature 
(Mabrey & Sturtevant, 1976). As expected, increased acyl chain length leads to a higher 
unfolding temperature and an increased enthalpy change during the gel-liquid phase 
transition due to the importance of van der Waals interactions in liposome bilayer 
stability. The inclusion of a negatively charged lipid, DSPG, with DSPC did not result in 
a change in Tm, as expected, because each of these lipids has an equivalent Tm. The 
enthalpy and cooperativity of the phase transition of IL-2 free liposomes including a 
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negatively charged lipid is altered due to the electrostatic interactions between head 
groups as expected.  
No significant change in the Tm, 
ΔT1/2, or ΔH of the lipid melting phase 
transition upon IL-2 incorporation was 
observed for DMPC, DPPC, and DSPC. 
The inclusion of a negatively charged 
lipid resulted in an alteration in the 
melting transition behavior upon IL-2 
incorporation behavior as shown by the DSC trace in FIGURE 19. Specific changes to 
the melting transition thermodynamic parameters for DMPC, DPPC, DSPC, and 
DSPC:DSPG liposomes upon IL-2 incorporation can be seen in TABLE 2. Because the 
thermal denaturation of IL-2 occurs over the same temperature range as the DPPC, 
DSPC, and DSPG lipids, the enthalpy values for the lipid phase transition were corrected 
for IL-2 unfolding enthalpy contributions. Incorporation of IL-2 into the lipid membrane 
of DSPC:DSPG liposomes leads to a decrease in the T1/2  from 2.42±0.3˚C to 
1.795±0.199˚C (P<0.01). The broadening peak upon IL-2 incorporation into these 
liposomes coincides with an increase in enthalpy from 19.1844±351.4 kcal/mol to 
25.4±2.31225 kcal/mol (P<0.05). 
 
 
 
 
FIGURE 19: Thermodynamic traces of DSPC:DSPG (10:1) 
liposomes +/- IL-2 using DSC.  
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4.3.3 Evaluation of Liposome Swelling and Aggregation Upon IL-2 Adsorption by 
Dynamic Light Scattering 
The liposomal particle size was measured by dynamic light scattering. Two 
phenomena can affect the particle size, and they are addressed separately here. The first 
item is the expected size increase due to IL-2 incorporation into the lipid bilayer. Let us 
first consider an empty liposome that has been extruded to a diameter of 
dLIPOSOME_ONLY=100nm. The surface area of this liposome (outer and inner leaflets), 
SALIPOSOME can be defined as a function of the diameter. The total surface of the 
liposome, SALIPOSOME can then be used to approximate how many lipid molecules are 
within the vesicle based upon the surface area of a single lipid head group, SALIPID, the 
thickness of the bilayer, t, and the total number of lipids within the vesicle, NLIPIDS. The 
surface are of a phosphatidylcholine lipid head group within a vesicle has been 
approximated to be 0.61-0.74nm2 (Huang & Mason, 1978; Murzyn, Rog, & 
Pasenkiewicz-Gierula, 2005), and a phosphatidylglycerol lipid head group has been 
estimated to be only 0.007nm2 smaller (Murzyn et al., 2005). We will therefore 
approximate the surface area of a single lipid (phosphatidylcholine or 
phosphatidylglycerol) as SALIPID=0.675nm2. The thickness of the bilayer in DMPC, 
DPPC, and DSPC liposomes, t, is 4.6, 5.2, and 5.9nm (Cornell & Separovic, 1983; Lewis 
& Engelman, 1983).  
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EQUATION 12 
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𝑁𝐿𝐼𝑃𝐼𝐷𝑆 =
𝑆𝐴𝐿𝐼𝑃𝐼𝐷
𝑆𝐴𝐿𝐼𝑃𝑂𝑆𝑂𝑀𝐸
 
EQUATION 13 
Based upon this calculation we can approximate that there are NLIPID=84871, 83864, and 
82706 lipid molecules within a 100nm DMPC, DPPC, and DSPC liposome, respectively. 
Assuming a similar acyl chain length as DSPC liposomes, NLIPID in a 100nm 
DSPC:DSPG (10:1) liposome is approximately  83573 lipid molecules. 
Now let us consider the case where IL-2 is incorporated into the liposomes. To 
calculate the new vesicle diameter increase upon IL-2 incorporation (dIL-2_LIPOSOME) , we 
must know how many IL-2 molecules we expect to incorporate (NIL-2) and the total 
surface area increase due to the incorporated IL-2 molecules (SAIL-2). The number of IL-
2 molecules we can expect to incorporate, NIL-2, can be calculated as a function of the 
molar ratio of protein to lipid (RIL-2:Lipid). The molar ratios as determined in section 4.3.2 
were used in this calculation. 
𝑁𝐼𝐿−2 = 𝑁𝐿𝐼𝑃𝐼𝐷𝑆𝑅𝐼𝐿−2:𝐿𝑖𝑝𝑖𝑑 
EQUATION 14 
The total increase in surface area due only to incorporated IL-2 molecules, SAIL-2, 
can be calculated as a product of the number of IL-2 molecules, NIL-2, and the surface 
area increased due to a single IL-2 molecule, SASINGLE_IL-2. 
𝑆𝐴𝐼𝐿−2 = 𝑁𝐼𝐿−2𝑆𝐴𝑆𝐼𝑁𝐺𝐿𝐸_𝐼𝐿−2 
EQUATION 15 
An approximation of the contribution of a single IL-2 molecule can be made on 
the basis of its crystal packing structure, which has an orthorhombic crystal lattice 
structure with dimensions of 3.171, 4.97, and 8.468nm (Arkin et al., 2003). Consider two 
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cases of IL-2 incorporation FIGURE 20. In case (a), each IL-2 molecule results in an 
increased surface area of SASINGLE_IL-2=3.171nm x 4.97nm. This will result in the 
smallest possible vesicle size increase. In case (b) each IL-2 molecule results in an 
increased surface area of SASINGLE_IL-2=8.468nm x 4.97nm. This will result in the largest 
possible vesicle size increase. We will consider these two extremes in our theoretical 
calculations. 
Finally, we determine the new diameter of the liposome with incorporated IL-2, 
dIL-2_LIPOSOME, by the following relationship. 
𝑆𝐴𝐼𝐿−2 𝐿𝐼𝑃𝑂𝑆𝑂𝑀𝐸 = 𝑆𝐴𝐿𝐼𝑃𝑂𝑆𝑂𝑀𝐸 + 𝑆𝐴𝐼𝐿−2 
EQUATION 16 
The diameter of the new IL-2 containing vesicle, dIL-2 LIPOSOME, is calculated 
according to the same strategy as the empty liposomal vesicle. 
FIGURE 20: Two possible orientations of IL-2 in lipid bilayer. Protein crystal structure image obtained from Protein Data 
Bank (PDB Identifier 1M47) 
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EQUATION 17 
  The diameter of this theoretical liposome, dIL-2Liposome, due to swelling upon IL-2 
incorporation was calculated and compared to experimentally determined liposome 
diameters obtained by DLS (FIGURE 21). Theoretical minimum increase in surface area 
assumes the longest portion of IL-2 is oriented parallel to lipid acyl chains, while 
theoretical maximum increase in surface area assumes the longest portion of IL-2 is 
oriented perpendicularly to the lipid acyl chains. The error bars for the theoretical values 
are indicative of minimum and maximum theoretical diameter increases as a result of the 
orientations in FIGURE 20. 
 
FIGURE 21: Average liposome particle size prior to and after IL-2 incorporation as measured with DLS and the 
theoretical size increase of liposomes upon IL-2 incorporation due to swelling. Data are presented as average±SD. For 
theoretical calculations, SD bars are based on the maximum and minimum liposome diameters upon IL-2 incorporation 
due to swelling. n=3. ***p<0.001. Statistical differences are indicated between the same lipid compositions. 
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FIGURE 21 shows that for empty, neutrally charged liposomes, as the lipid acyl 
chain length of neutrally charged liposomes increases, the average particle size in the 
population increases. However the incorporation of IL-2 into these neutrally charged 
liposomes leads to a significant decrease in diameter. The diameter of the IL-2 liposome 
increases by approximately 40 and 100% for DPPC and DSPC liposomes, respectively, 
as compared 100nm diameter the liposomes were initially extruded at. However, the 
theoretical diameters of IL-2 liposomes composed of neutrally charged lipids based upon 
swelling do not significantly differ from these experimentally determined values. This 
suggests that the increase in diameter of the neutrally charged liposomes can be explained 
by swelling upon IL-2 incorporation into the bilayer. 
The opposite event occurs upon IL-2 incorporation into a negatively charged 
liposome (DSPC:DSPG).  DSPC:DSPG liposomes with no IL-2 have an average 
FIGURE 22:(a) Histogram of DMPC liposome particle sizes prior to IL-2 incorporation as measured by DLS. (b) Line 
graph adapted from histogram data to allow for easier visual comparison between samples. 
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diameter of 116.15nm, which is very close to the 100nm diameter at which they were 
initially extruded at. However, the particle diameter increases 3 fold upon IL-2 
incorporation. Because this increased IL-2 liposome diameter is significantly different 
than the theoretically calculated diameter upon IL-2 incorporation (p<0.001), swelling 
due to protein incorporation does not appear to be the only cause. 
While swelling is certainly one factor that may affect the average particle 
diameter determined by DLS, aggregation may also lead to this result. To further 
investigate whether aggregation has occurred, we analyzed the size distribution of 
FIGURE 23: Liposome diameter distribution prior to and after IL-2 incorporation in DMPC, DPPC, DSPC, and 
DSPC:DSPG liposomes. 
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liposomes in solution prior to and after IL-2 incorporation. From the DLS data, we obtain 
a distribution of all measured particle sizes within a liposome population. A histogram of 
these particle sizes within a DMPC liposome population prior to IL-2 incorporation is 
shown in FIGURE 22a.  To allow for visual comparison of any shifts or widening of the 
population distribution, FIGURE 22a can also be visualized with a line graph as in 
FIGURE 22b. We have chosen to display the size distribution in this manner for the rest 
of the data. 
 
FIGURE 23 shows how the size distribution of liposomes prior to and after 
incorporation of IL-2 is affected. Aggregation is typically manifested as a widening and 
skewing of the size distribution (Volodkin, Ball, Schaaf, Voegel, & Mohwald, 2007). The 
size distribution shape of DMPC and DPPC liposomes does not change prior to and after 
IL-2 incorporation. This suggests that IL-2 incorporation does not induce DMPC or 
DPPC liposome aggregation. The similarly shaped distribution peak of IL-2 DSPC 
liposomes indicates that these IL-2 liposomes do not aggregate. While no aggregation is 
seen for neutrally charged liposomes composed of DMPC (+/- IL-2), DPPC (+/-IL-2), or 
DSPC (+IL-2), empty DSPC liposomes do appear to aggregate as evidenced by a 
widening of the size distribution peak. FIGURE 23 also shows that negatively charged 
DSPC:DSPG liposomes with no IL-2 do  not appear to aggregate, but do appear to 
aggregate upon IL-2 incorporation as evidenced by a widening and skewing of the peak. 
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Because aggregation is suggested by DLS data in DSPC liposomes without IL-2 
and DSPC:DSPG liposomes containing IL-2, we will expound upon how many liposomes 
appear to be aggregating together in each formulation. To do this, we can make a 
comparison of the size distribution range of each of these formulations with theoretically 
calculated liposome aggregate sizes. Consider n=1,2,3…vesicles with diameter, d, 
aggregating together. The diameter of the sphere, D, 
that these aggregates fit within, as shown in FIGURE 
24, are measured as the particle size by DLS. Assuming 
a spherical vesicle shape and assuming these spheres do 
not overlap, the diameter of the sphere containing the 
vesicle aggregates, D, can be calculated geometrically. 
These values have been calculated by Kravitz (Kravitz, 
1967). We have calculated the theoretical size of empty 
DSPC liposomes based upon a liposome diameter size 
of 100nm. Calculations for DSPC:DSPG liposomes 
with IL-2 are based on a ‘swollen’ liposome size of 
150.878nm (FIGURE 21). Based on the aggregate sizes 
calculated by FIGURE 24 and the size distributions 
given by FIGURE 23, empty DSPC liposomes tend to aggregate in groups of 
approximately 6-7, while IL-2 DSPC:DSPG liposomes tend to aggregate in groups of  4. 
 
 
 
FIGURE 24: Diameter of smallest 
sphere, D, containing n number of 
smaller spheres of identical 
diameter, d. Values of D based upon 
d calculated by Kravitz (Kravitz, 
1967). 
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4.3.4 In Vitro IL-2 Release Kinetics From Liposome: Effect of Liposome Composition 
 
FIGURE 25: Release kinetics of IL-2 from (a) DMPC, DPPC, and DSPC liposomes and (b) DSPC and DSPC:DSPG 
(10:1) liposomes 
 
 
 
FIGURE 25 shows the in vitro release kinetics of IL-2 from neutral and charged 
liposomes, evaluated using a dialysis sample and replace method. Non-incorporated, free 
IL-2 was removed from the liposome suspension prior to release kinetics evaluation, and 
it was assumed that all IL-2 was incorporated at time zero (i.e. 100% of the IL-2 was 
liposome bound). Release kinetics were evaluated over the first 6 hours. After each 
hourly sampling period, the released IL-2 was removed and fresh water was added to the 
reservoir to continue to drive diffusion of released IL-2 from the sample dialysis chamber 
(see section 4.2.7). FIGURE 25a depicts the effects of acyl chain length in neutrally 
charged liposomes, while FIGURE 25b shows the effects of the incorporation of a 
negatively charged head group. Each release profile follows an exponential release 
kinetic model, which has been observed in the literature of IL-2 liposomes (Neville, Boni, 
et al., 2000).  
𝐼𝐿2𝑏𝑜𝑢𝑛𝑑(𝑡) = 100[𝑒−𝑘𝑡] 
EQUATION 18: Exponential kinetic release model, where IL2bound(t) is the percentage of IL-2 remaining bound to the 
liposome at time, t (measured in hours), and K is the rate of IL-2 released, expressed in hr-1. 
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           The rate of IL-2 released, k (hr-1), decreases as the acyl chain length increases in 
neutrally charged liposomes DMPC, DPPC, and DSPC (p<0.001). As a comparison, an  
exponential fit from data extrapolated from Nevile et al and fit with EQUATION 18 
revealed an in vitro release rate of IL-2 from 177nm DPPC liposomes of approximately 
k=0.2126hr-1, which differs from our value by ~13%. Furthermore, the inclusion of a 
negatively charged lipid with DSPC (DSPC:DSPG) decreases the rate of IL-2 released in 
vitro by nearly 30%.  
 After the first 6 hours, the remaining IL-2 liposome constructs were incubated overnight. 
While hourly sampling and replacing of release media in the reservoir does drive 
diffusion and thus ultimately affects the release kinetics observed, this still allowed us to 
make comparisons between formulations of total released IL-2 after 24hours. After 24 
hours, there was 5.853±0.847, 8.320±1.827, 28.898±5.203, and 45.305±3.387% IL-2 
remaining bound to liposomes. Because the experimental parameters were not identical, 
no direct comparison between the exponential model used for IL-2 release during the first 
6 hours and the amount of IL-2 released after the remaining 18 hours can be made. 
Rather, the second portion of the release kinetic experiment reflects the nature of the 
chemical thermodynamic equilibrium state of binding and association. As shown by the 
results obtained from ITC, the binding constant increases as acyl chain increases. The 
TABLE 3: Exponential kinetic release model parameters for IL-2-liposomes. All release rates are significantly different 
(p<0.001); n=3. 
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binding constant is a function of the concentrations of free and bound components, and 
reflects the likelihood of a bound complex. IL-2 binds to DSPC liposomes with a higher 
binding constant than DMPC, thus there is a higher probability of IL-2 binding the DSPC 
liposomes than DMPC liposomes at any given time.   
4.3.5 Bioactivity of Released IL-2: Effect of Liposome Composition 
 Bioactivity of IL-2 was assessed by its ability to prevent CTLL-2 cell death and lead to 
cell proliferation (See section 2.2.4). No decrease in bioactivity was seen in any samples, 
indicating IL-2 released from the carrier did not result in structural changes that affected 
bioactivity.  
 
4.4 Discussion 
In this study, we were interested in evaluating the effect of liposome lipid 
composition on IL-2 liposome interaction as evidenced by binding thermodynamics, 
membrane perturbations, IL-2 release kinetics, and functional retention of IL-2. Because 
To avoid thermal and mechanical stresses associated with encapsulation of the protein 
FIGURE 26: Bioactivity of released IL-2 from liposomes. Bioactivity of IL-2 is a function of its ability to lead to CTLL-2 
viability (a) and number of cell proliferation cycles among cells that remained viable (b) 
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within the interior of the liposome, we chose to absorb IL-2 onto preformed liposome 
bilayer membranes. Lipid acyl chain effects were examined by formulating with neutrally 
charged lipids of acyl chain lengths 14, 16, and 18 carbons (DMPC, DPPC, and DSPC, 
respectively). The effect of a negative charge inclusion was probed by formulating a 
DSPC:DSPG (10:1) liposome, which is composed of lipids with 18 carbon acyl chains.  
The choice to include a phosphatidylglycerol (PG) based lipid, which has a net charge of 
(-1) at pH 7.4, was based upon its inclusion within several IL-2 liposome formulations in 
the literature (P. M. Anderson et al., 1990; Bergers et al., 1993; Boni et al., 2001; 
Kanaoka et al., 2001, 2003; Kanaoka et al., 2002; F. J. Koppenhagen et al., 1998). PG has 
been used in literature to promote IL-2 – liposome association by electrostatic interaction 
(Bergers et al., 1993) and to prevent liposome aggregation. Electrostatic interaction is 
often thought to precede adsorption at solid/liquid interfaces (Adamczyk & Warszyński, 
1996).  
In this study, we have demonstrated evidence that IL-2 associates with neutral and 
negatively charged liposomes through a predominantly hydrophobic interaction. 
Predominantly hydrophobic interaction between IL-2 and the lipid acyl chains as opposed 
to electrostatic interaction is demonstrated by alterations in the thermodynamic binding 
parameters (obtained by ITC) as the acyl chain length is changed within neutral liposome 
formulations, but no modification in the thermodynamic parameters when a negatively 
charged lipid (DSPG) is included within the formulation. While ITC has been used to 
quantify protein-lipid interactions in the literature (Schote, Ganz, Fahr, & Seelig, 2002; 
Swamy & Sankhala, 2013), this is the first time to our knowledge that the thermodynamic 
parameters of binding (enthalpy and entropy contributions, binding constants) for an IL-2 
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liposome system has been quantified. Our ITC results showed that the enthalpy 
contributions to binding (ΔH) are approximately two orders of magnitude smaller than 
the entropic contribution (TΔS) in all liposome formulations, regardless of lipid 
composition. This entropic contribution increases as the acyl chain length (and thus the 
area available for hydrophobic interaction with IL-2) increases. However, because no 
statistical difference in the entropic contributions is seen between IL-2 binding to neutral 
(DSPC) or charged (DSPC:DSPG) liposomes, electrostatic contributions to binding are 
likely to be minimal (FIGURE 18). These large entropic changes are indicative of a 
disruption of the orderly clathrate water structures surrounding free IL-2 in solution (a 
system with a very low entropy) as the protein enters the acyl chain region of the lipid 
bilayer and the solvent water molecules are free to assume a wide variety of arrangements 
(a system with much higher entropy). The minimal enthalpy contributions observed are 
due to electrostatic interaction, van der Waals interactions, and H-bonds. (Swamy & 
Sankhala, 2013; Tanford, 1980).  
The importance of hydrophobic interaction between IL-2 and the acyl chains of 
the lipid bilayer within a liposome system is further supported by the protein: lipid molar 
ratios and binding constants obtained for each system by ITC. As the acyl chain length of 
neutrally charged liposomes (DMPC, DPPC, and DSPC) is increased, IL-2:lipid molar 
ratio (FIGURE 16) and binding constant between IL-2 and the lipid bilayers (FIGURE 
17) are increased. However, there is no difference in the strength of the binding 
interaction between IL-2 and neutral (DSPC) or charged liposomes (DSPC:DSPG) 
(FIGURE 17). One possible reason for an increased IL-2 incorporation into liposomes 
with longer acyl chains is that the thickness of the bilayer, and thus the hydrophobic 
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surface area of the bilayer with which IL-2 can interact, is larger. The lengths of DMPC, 
DPPC, and DSPC acyl chains have been calculated elsewhere to be 2.3, 2.6, and 2.95 
±0.01nm, respectively (Lewis & Engelman, 1983). We will approximate the acyl chain 
region of these lipid bilayers to be twice these values, which means that the thickness of 
DMPC, DPPC, and DSPC bilayers would be expected to differ by 0.6-1.3±0.02nm.  This 
difference in length is comparable to the dimensions of a single IL-2 crystal molecule, 
which has an orthorhombic crystal lattice structure with dimensions of 3.171, 4.97, and 
8.468nm (Arkin et al., 2003). A second reason for the difference in stoichiometry 
between IL-2 and DMPC, DPPC, and DSPC liposomes may be the difference in bilayer 
acyl chain packing. This is the predominant structural change that occurs as acyl chain 
increases (Cornell & Separovic, 1983). Increased packing may increase the ability of IL-2 
to interact with lipid bilayers due to the proximity between the protein and the bilayer 
hydrophobic chains.  
In addition to the ITC evidence for a predominantly hydrophobic interaction 
between IL-2 and the hydrophobic acyl chain region, this hydrophobic interaction also 
appears to impact the rate at which IL-2 is released as shown in FIGURE 25a. While 
there is not a direct mathematical relationship between the binding strength constant, 
Kassociation (M-1), and the release rate constant, k (hr-1), given in EQUATION 18, there is a 
correlation in this work. The larger binding constant for IL-2 to neutral lipids with longer 
hydrophobic acyl chains results in a slower release rate of IL-2 in vitro.  
DSC was used to further probe the interaction of IL-2 and liposomes to infer the 
location of IL-2 within the bilayer. The lamellar gel to liquid-crystalline phase changes 
(i.e. melting) of bilayer lipids have been studied as a means of probing solute and protein 
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interaction with lipid membranes. During this cooperative transition hydrophobic acyl 
chains in a rigid, extended, all-trans conformation increase in intra- and intermolecular 
motion and many chains change to a gauche conformation (Ruthven & Ronald, 2011). 
Alterations to the thermodynamic parameters of this lipid phase transition upon protein 
incorporation or adsorption have been categorized according to the manner in which 
proteins interact with the bilayer as detailed in 4.2.5. Category 1 proteins associate with 
the lipid head group through predominantly electrostatic interaction, category 2 proteins 
are incorporated within both the lipid head group and acyl chain regions, and category 3 
proteins associate with only with the lipid acyl chains (Lo & Rahman, 1995).   DSC 
revealed no change in thermodynamic parameters for DMPC, DPPC, and DSPC 
liposomes. Indeed, IL-2 adsorption onto DPPC liposomes has been shown in literature to 
result in no significant difference in thermodynamic parameters of lipid melting (F. J. 
Koppenhagen et al., 1998). This is indicative of a category 1 or category 2 proteins as 
given in TABLE 1. Given the evidence of hydrophobic interaction between IL-2 and 
neutral or anionic liposomes, we suspect that IL-2 behaves more like a category 2 protein.  
Further support for IL-2 as a category 2 protein is given by the alteration of the 
anionic (DSPC:DSPG) lipid bilayer melting phase transition parameters. IL-2 
incorporation into anionic DSPC:DSPG liposomes results in an increase in ΔH in a 
similar manner as cytochrome c, a category 2 protein (when formulated above a 4% 
molar protein to lipid ratio) (Demetzos, 2008).  However, while IL-2 did alter the ΔT1/2 
upon incorporation into anionic liposomes (DSPC:DSPG) like cytochrome c upon 
incorporation to DSPG liposomes, the alteration was not identical (TABLE 2). 
Cytochrome c results in an increase in ΔT1/2 of DSPG lipid bilayers (when formulated 
89 
 
above a 11.5% molar protein to lipid ratio) while IL-2 resulted in a decreased ΔT1/2 upon 
incorporation to DSPC:DSPG lipid bilayers. The difference between IL-2 and 
cytochrome c may be due to the lower incorporation of IL-2 as compared to cytochrome 
c in the DSC studies. IL-2 was able to be formulated at no higher than 3.4% molar 
protein: lipid ratios, while cytochrome c was formulated at concentrations above 11.5% 
in DSPG lipid bilayers (Lo & Rahman, 1995). It is also possible that the thermodynamic 
parameter changes to the lipid bilayer melting phase transition observed for IL-2 
DSPC:DSPG liposomes as compared to (IL-2 free) DSPC:DSPG liposomes is a function 
of liposomal aggregation upon IL-2 incorporation. Aggregation of lipid bilayers may 
increase the stability of the liposome bilayer structure, ultimately increasing the enthalpic 
contribution (increased ΔH) required to disrupt this new, more complex lipid structure. 
By the same logic, the cooperativity of this new, more integrated, aggregated liposomal 
structure could be expected to be higher (decreased ΔT1/2). Both of these phenomena are 
seen in our work.  
In addition to the observance of a chiefly hydrophobic IL-2 liposome interaction, 
we have also seen evidence for liposome vesicle aggregation and de-aggregation 
phenomena upon IL-2 incorporation. DLS was used to determine the average size of the 
liposomes before and after extrusion. While neutrally charged, empty DMPC liposomes 
show no aggregation, there was a three-fold increase in the average liposome particle size 
as the acyl chain length of the lipids increases from 14 carbons (DMPC) to 18 carbons 
(DSPC) in neutrally changed liposomes. Some aggregation is expected in liposomes with 
composed of neutrally charged lipids due to a lack of electrostatic surface repulsion, but 
we observe aggregation phenomena dependent on chain length. This may be attributed to 
90 
 
localized surface charge distribution. While phosphatidylcholine based liposomes are 
composed of lipids with an overall neutral charge, they do exhibit a very small negative 
surface charge at low ionic strengths (Makino et al., 1991), with this charge being 
strongest for DMPC and weakest for DSPC. The reason for this is due to the orientation 
of the head group. Phosphatidylcholine lipids have a negatively charged phosphate group 
and a positively charged choline group. At low ionic strengths, DMPC, DPPC, and DSPC 
the positively charged choline group is buried within the bilayer, while the phosphate 
portion in oriented such that it is closer 
to the surface of the bilayer. The angle 
between the lipid head group and acyl 
chain increases as the acyl chain length 
increases due to lipid molecule packing 
constraints, leading to more equal 
surface exposure of the negative and 
positive charges on the lipid head group (Makino et al., 1991) (FIGURE 27). This would 
be expected to result in a decreased electrostatic repulsion between vesicles, and thus 
aggregation. Indeed, such a trend is reflected in our data for the phosphatidylcholine 
lipids before IL-2 incorporation for DSPC liposomes (FIGURE 21). Not surprisingly, 
empty DSPC:DSPG liposomes, which have an overall negative charge, electrostatically 
repel one another and resist aggregation. As shown in FIGURE 21, empty DSPC:DSPG 
liposomes exhibit good colloidal stability and retain an average particle size of 116nm. 
While empty DSPC liposomes aggregated and empty DSPC:DSPG liposomes did 
not, aggregation phenomena of neutrally and negatively charged liposomes composed of 
FIGURE 27: Nuetral lipid head group orientation as a 
function of acyl chain length 
91 
 
18 carbon acyl chains were altered upon IL-2 incorporation. IL-2 incorporation to DSPC 
liposomes causes a marked narrowing of the particle size distribution (FIGURE 23) and 
an average particle size that is significantly smaller than the empty liposome (FIGURE 
21). Furthermore, the average size of the IL-2 liposomes is not statistically different than 
the theoretically calculated value. Thus the aggregation phenomena observed in the 
empty DSPC liposomes is reversed after IL-2 incorporation suggesting that vesicle fusion 
is not responsible for larger vesicle size observed in empty DSPC liposomes. 
Upon incorporation of IL-2, negatively charged DSPC:DSPG liposome particle 
size increases by a factor of 3. Aggregation of negatively charged liposomes has been 
observed in the literature upon protein incorporation into the bilayer (Kiyota, Lee, & 
Sugihara, 1996; Persson, Thorén, & Nordén, 2001). Kiyota et al evaluated the 
incorporation of small, amphiphilic, α-helical model peptides composed of hydrophobic 
leucine and positively charged lysine amino acids into neutral and charged liposomes. 
Incorporation into neutrally charged 
liposomes did not cause vesicle 
aggregation, but incorporation of some 
amphiphilic peptides into anionic 
liposomes did, as evidenced by turbidity 
measurements. The aggregation of anionic 
liposomes occurred when the positively 
charged residues were exposed on the 
liposome surface, allowing for interaction 
with neighboring anionic vesicles (Kiyota FIGURE 28: Hydrophilic and neutral regions of IL-2 
(image from Protein Data Bank viewer, PDB Identifier 
1M47) 
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et al., 1996).   While IL-2 is a relatively hydrophobic cytokine, it does have both 
hydrophilic and hydrophobic regions (C. A. Bergmann, Landmeier, & Kaplan, 1991). 
These hydrophilic, hydrophobic, and neutral subunits of IL-2 have been evaluated by 
Bergman by the generation of a hydrophilicity plot using the Hopp Woods method. 
Hydrophilic subunits were found to lie between amino acid residues 47-56 and 95-133 
(Christoph Alexander Bergmann, 1991). These sections contain four positively charged 
amino acids at Arg 120, Lys 48, Lys 49, and Lys 54. The hydrophilic and neutral regions 
of IL-2 have been circled in FIGURE 28.  
 Assuming that amphiphilic IL-2 interacts with neutral and anionic liposomes in a similar 
manner as described for small amphiphilic helical peptides by Kiyota et al (Kiyota et al., 
1996),  we have proposed a theoretical interaction for IL-2 to DMPC, DPPC, DSPC, and 
DSPC:DSPG liposomes, shown in FIGURE 29. Because the hydrophilic and 
hydrophobic residues are clustered together 
(FIGURE 28), the proposed model shown 
may not necessarily require major protein 
conformational structure alterations upon 
IL-2 incorporation. The hydrophobic 
portion of the protein embeds within the 
lipid acyl chain region, while the more 
hydrophilic regions are excluded from this 
hydrophobic region (Groves, 2006). The 
more hydrophilic region of the protein 
extends into the aqueous environment. We 
FIGURE 29: Proposed interaction model for IL-2 
interaction with DMPC, DPPC, DSPC, and DSPC:DSPG 
liposomes. 
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will assume that this region includes Lys 48, Lys 49, Lys 54 and Arg 120 (Christoph 
Alexander Bergmann, 1991), which are all positively charged.  Because the hydrophobic 
regions of the protein outnumber the hydrophilic regions, the bulk of the protein is 
assumed to be embedded within the hydrophobic acyl chains. This would lead to a larger 
hydrophobic involvement in binding, which is supported by the larger entropic 
contribution observed by our ITC experiments. Evidence for a mainly hydrophobic 
interaction is also corroborated by the observed dependence of stoichiometry and the 
binding constant on acyl chain length, as previously discussed. Our ITC data also 
suggests a small amount of electrostatic interaction between IL-2 and neutral as well as 
anionic liposomes (FIGURE 18b), which also supports our proposed model (FIGURE 
29). Furthermore, there is evidence in the literature supporting such a model. Neville et al 
observed disturbances in the acyl chain region of DMPC liposomes upon IL-2 
incorporation, indicating IL-2 at least partially partitioned within the hydrophobic bilayer. 
Part of the IL-2 molecule was also displayed on the surface of the liposome as evidenced 
by the ability of an anti-IL-2 antibody to bind to the IL-2 liposome (Neville, Boni, et al., 
2000).  Koppenhagen et al observed no change to secondary structure upon IL-2 
incorporation into DPPC liposomes, but did see a change in the steady state fluorescence 
of the single tryptophan (Trp) residue in IL-2. This residue, Trp121, is next to Arg 120, 
which is one of the cationic amino acids that we propose to be extended outside the 
hydrophobic acyl chains (F. J. Koppenhagen et al., 1998).   
94 
 
This proposed theoretical model of IL-2 liposome interaction also explains the 
liposome aggregation and de-aggregation phenomena observed upon incorporation IL-2 
incorporation into DSPC and DSPC:DSPG liposomes as shown in FIGURE 30. Empty 
DSPC liposomes (FIGURE 30a) tend to aggregate due to a lack of electrostatic repulsion, 
resulting in the increased aggregation observed in our work. Based on the theoretical 
model of IL-2 lipid interaction, exposed hydrophilic regions of the protein containing Lys 
or Arg (positively charged) would lead to  electrostatic repulsion of IL-2 DSPC 
liposomes (FIGURE 30b). Thus IL-2 incorporation into DSPC liposomes serves to 
increase the colloidal stability of the liposome vesicle in a similar manner as other 
hydrophilic polymer surface coatings used in liposome formulations (Mufamadi et al., 
FIGURE 30: Aggregation and de-aggregation due to IL-2 incorporation to neutral and anionic liposomes. (a) 
Aggregation of neutrally charged empty DSPC liposomes. (b) Exposure of positively charged residues on hydrophilic 
regions of IL-2 on the surface of the DSPC liposome increases electrostatic repulsion between the surfaces of IL-2 
DSPC liposomes. (c) Colloidal stability (no aggregation) of empty anionic DSPC:DSPG (10:1) liposomes. (d) 
Exposure of positively charged residues on hydrophilic regions of IL-2 on the surface of the DSPC:DSPG liposome 
results in electrostatic attraction with negatively charged PG head groups of neighboring vesicles. 
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2011). Empty DSPC:DSPG liposomes (FIGURE 30c), do not tend to aggregate due to the 
electrostatic repulsion between the negatively charged head groups. Incorporation of IL-2 
into DSPC:DSPG liposomes (FIGURE 30d) may lead to aggregation due to electrostatic 
attraction between the exposed positive charges on the liposome surface and the 
negatively charged PG head groups of neighboring IL-2 DSPC:DSPG liposomes.  
 This proposed theoretical model of interaction and its role in aggregation also clarifies 
some of the observations not entirely explained by hydrophobic interactions. For 
example, the release rates of IL-2 from neutrally charged liposomes correlate with the 
length of the hydrophobic acyl chain. By this logic, the IL-2 release rate from 
DSPC:DSPG liposomes should be similar that to that of DSPC liposomes. However we 
observe IL-2 releases more slowly from DSPC:DSPG liposomes than DSPC liposomes 
(FIGURE 25). Furthermore, we observed that upon further release over 24hours, a larger 
amount of IL-2 was retained by DSPC:DSPG liposomes as opposed to DSPC 
(28.898±5.203% IL2 remaining bound to DSPC liposomes versus 45.305±3.387% for 
DSPC:DSPG liposomes. Aggregation of DSPC:DSPG liposomes containing IL-2 could 
result in IL-2 that is trapped between vesicles, ultimately slowing release during the 6 
hour sample and replace dialysis release kinetic experiment (FIGURE 25) and increasing 
the amount of IL-2 not released during the next 18 hours of dialysis (see section 4.3.4), as 
compared to neutrally charged DSPC IL-2 liposomes.  
The aggregation behavior of IL-2 DSPC:DSPG liposomes may also explain why 
the ratio of protein to lipid is lower for DSPC:DSPG versus DSPC (0.083±0.004 for 
DSPC versus 0.052±3.3E-4, p<0.001 for DSPC:DSPG, FIGURE 16) even though there is 
no statistical difference between these two formulations with regards to binding strength 
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(Kassociation) or enthalpy and entropy contributions to binding. The lower amount of 
protein incorporated into DSPC:DSPG liposomes may be a reflection of decreased 
available liposome surface area available for binding due to aggregation upon IL-2 
incorporation to these anionic liposomes. 
Finally, bioactivity of released protein was not altered as evidenced by FIGURE 
26. This is a very promising result and may be a reflection of the how IL-2 is 
incorporated within the lipid bilayer. Our model assumes that the distinct regions of 
hydrophobicity and hydrophilicity shown in FIGURE 28 remain grouped together within 
the lipid bilayer (FIGURE 29). Such a model may not require major protein 
conformational changes from the native structure. Indeed, no major structural alterations 
upon IL-2 incorporation to DPPC liposomes were observed by Koppenhagen et al as 
evaluated by circular dichroism (F. J. Koppenhagen et al., 1998). 
4.5 Conclusions 
In this work we sought to evaluate the biomolecular interactions between IL-2 and 
liposomes composed of phosphatidylcholine based lipids and a mixture of 
phosphatidylcholine and phosphatidylglycerol lipids in order to aid in the rational design 
of IL-2 liposome drug delivery constructs. The effect of acyl chain length and lipid 
charge on protein-lipid interaction and the subsequent implications for pharmaceutical 
formulation were considered. We found that hydrophobic interaction of IL-2 with the 
lipid acyl chains was the primary driving force behind IL-2 and liposome incorporation in 
each case, and that an increase in acyl chain length led to a more efficient and tightly 
bound IL-2 – liposome compound. Bioactivity of released protein was not significantly 
altered. However, incorporation of IL-2 into these liposomes significantly changed the 
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size and aggregation behavior of the vesicles, and ultimately the kinetic release IL-2, 
elements that ultimately influence the pharmaceutical and pharmacokinetic behavior of 
drug loaded liposomes in vivo.  
The effect of IL-2 incorporation into lipid vesicles is extremely important to 
consider in rational drug delivery system design.  Our data indicates that higher IL-2 
incorporation ratios and slower release kinetics may be obtained for IL-2 liposomes may 
be obtained by formulating with lipids with longer acyl chains. While negatively charged 
lipids are often included in liposomal formulations to prevent aggregation, anionic 
liposomes tend to aggregate when formulated with IL-2 within the bilayer. Neutrally 
charged liposomes, which are often assumed to aggregate due to a lack of electrostatic 
interaction, have excellent colloidal stability (i.e. do not aggregate) when formulated with 
IL-2 within the bilayer. Aggregation of IL-2 loaded anionic liposomes slowed the release 
rate, but also decreased the protein to lipid molar ratio. Depending on the therapeutic 
goal, one formulation may be preferred to the other. While aggregation of nanoparticles 
intended for circulation is not desired, it may be desirable in a depot controlled release 
construct.  
 
 
 
CHAPTER 5: CONCLUSIONS, IMPLICATIONS, AND FUTURE DIRECTIONS 
 
 
In this work we have evaluated specific stability issues of IL-2, a pharmaceutical 
protein, within aqueous and lipid environments. We chose the evaluate IL-2 thermal 
stability within an aqueous environment. The ability to withstand thermal stress is 
particularly relevant for IL-2 because its thermal denaturation pathway is irreversible. 
Thermal stress also speeds some of the denaturation pathway rates specific to IL-2, such 
as oxidation, deamidation, and aggregation (Cadee et al., 2001; Philo & Arakawa, 2009; 
Sasaoki et al., 1992; K. D. Weaver et al., 2012). Thermal stress is often a factor in 
liposome formulation as well; to achieve encapsulation of a protein drug within the 
aqueous compartment of a liposome, the protein and liposome is traditionally heated 
together to at least 10˚C above the thermal transition temperature of the lipids before size 
homogenization via extrusion or sonication. Therefore lipid choice is often limited to low 
transition temperature lipids, and it was of interest whether mitigation of such thermal 
stresses with the excipients examined in this work could allow a wider selection range of 
lipids for liposome formulation.  
We chose a promising organic salt, CDHP, as a possible thermal stabilizer of IL-2 
on the basis of previous studies by our lab and others which found CDHP increased the 
thermal midpoint transition temperature (Tm) of model proteins formulated with CDHP. 
We examined specific ion effects and found that the conformational stability imparted to 
IL-2 was primarily due to the presence of the kosmotropic ion, dihydrogen phosphate. 
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While high concentrations of CDHP were able to increase the Tm of IL-2 and impart 
conformational stability to the protein at temperatures above this temperature, 
formulating IL-2 with CDHP does come at a bioactivity cost. This decrease in bioactivity 
was proposed to originate from the same factors responsible for the increase in thermal 
and conformational stability. CDHP contains a kosmotropic ion, which tends to 
preferentially interact with the water molecules surrounding the protein, thereby 
kinetically protecting IL-2 from perturbations of bulk water molecules. However this 
kinetic stability may result in a decrease in molecular mobility required for full IL-2 
bioactivity. If thermal stress is unavoidable, CDHP may be used to thermally stabilize the 
protein; however protein concentrations must be adjusted to account for the change in 
bioactivity of the final product. In this work we also explored formulation options that 
avoided thermal stress by IL-2 encapsulation into liposomes. IL-2 was successfully 
adsorbed onto the bilayer of liposomes, with a clear relationship between acyl chain 
length and the IL-2: lipid ratios obtained. The lipid showing the highest strength 
interaction with IL-2, DSPC, would have been restricted from use if traditional 
encapsulation methodologies had been chosen because the protein would have to be 
heated above its Tm. By avoiding thermal and mechanical stress and adsorbing IL-2 to 
preformed liposomes, the bioactivity of the subsequently released IL-2 was maintained. 
The interaction between IL-2 and the lipids chosen in this study was driven 
primarily by hydrophobic mechanisms. It was also found that because the incorporation 
of IL-2 into the lipid bilayer presumably changed the surface charge distribution, 
aggregation phenomena of the final product, not just the IL-2 free liposome, is extremely 
important to consider. Aggregation and de-aggregation phenomena occur after IL-2 
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incorporation to neutral and charged liposomes based upon the deviation of liposome size 
from the extruded size upon IL-2 incorporation are particularly relevant from a 
therapeutic standpoint. Liposome carrier size is an extremely important variable in 
targeting of specific tissues, organs, or systems. For example, although it has not been 
attempted before, targeting of IL-2 to the lymphatic system using a liposomal carrier has 
promise due to the unique action of this drug. It has been proposed in literature that the 
adverse effects of this immunotherapeutic are associated with IL-2 interaction with 
certain entities within the blood stream (namely natural killer cells and neutrophils), 
while the beneficial effects are due to the interaction of the protein with IL2R expressing 
activated CD4+ T-cells, which reside largely in the lymphatic system (Caligiuri, 1993; 
Stites, 1994; van Haelst Pisani et al., 1991). By this logic, targeting of the lymphatic 
system may enhance the therapeutic benefits of IL2 therapy, while limiting toxicity. 
While several routes to target the lymphatic system exist including, intradermal (i.d) (A. 
Supersaxo, Hein, Gallati, & Steffen, 1988), intraperitoneal (i.p.) (Maincent et al., 1992), 
intragastric (Potluri & Betageri, 2006), and pulmonary routes, it has been found that 10-
100nm sized liposomes are efficiently transported from subcutaneous tissue into the 
lymphatic system (Christien Oussoren & Storm, 2001; C. Oussoren et al., 1998; C. 
Oussoren et al., 1997; Zuidema et al., 1994). Because IL-2 incorporation into neutral 
liposomes increased vesicle diameter by up to 3 fold (from the extruded diameter) in 
DSPC formulations, liposomes intended for subcutaneously administered lymphatic 
targeting must be extruded at smaller diameters. Further study is needed to optimize the 
size upon extrusion and protein lipid molar ratios. 
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Because nanoparticles are commonly injected into the body with the expectation 
that they will circulate to some desired region in the body, aggregation of nanoparticles is 
not typically desired. However aggregation may hold promise as a liposomal 
depot/reservoir. For example, subcutaneous or intramuscularly administered liposomes 
that aggregate will not be able to diffuse into blood or lymphatic circulation, but may 
release their cargo locally. Maintaining low levels of locally administered IL-2 has been 
shown to result in better therapeutic outcomes rather than high doses of systemic IL-2 
(Bubeník, 1990; Bubenik & Indrova, 1987; Den Otter et al., 2008).  
The results from these studies have revealed the sensitivity of IL-2 to thermal 
stress, and revealed the potential tradeoffs between thermal stability and bioactivity. 
Given this data, we have formulated several liposomal carriers without exposure to 
thermal stress that were able to release bioactive IL-2. We have characterized the nature 
of the interaction between these carriers and IL-2 and have evaluated any aggregation 
effects. These results may aid in the further development of targeting liposomal systems 
or depot drug delivery designs for IL-2. Formulating liposomes composed of the longest 
acyl chains (DSPC and DSPC:DSPG) resulted in the highest protein incorporation ratios 
and the slowest release of IL-2 in vitro. While IL-2 liposomes composed of neutrally 
charged lipids showed little to no aggregation, anionic IL-2 liposomes (DSPC:DSPG) 
showed significant aggregation tendency. Aggregation not only has an impact on the 
pharmacokinetics of nanoparticle carriers, but it also has an impact on the interaction 
between IL-2 and the lipid membrane.  Aggregated DSPC:DSPG IL-2 liposomes resulted 
in a slower release of IL-2. Furthermore, aggregation of anionic liposomes upon IL-2 
incorporation may have decreased the protein to lipid molar ratios obtained. Depending 
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on the pharmacokinetic, release profile, and dosing needs, these data suggest that lipid 
acyl chain length and lipid charge can be optimized to control these relevant 
pharmaceutical parameters.  
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